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12 1 Introduction 
A Zusammenfassung 
Die Ordnung der Actinomycetales ist bekannt für die Produktion einer Vielzahl von Naturstof-
fen mit unterschiedlichen Indikationen. Im Rahmen dieser Arbeit wurden daher neue Natur-
stoffe innerhalb der Tübinger Stammsammlung, welche mehr als 1000 Stämme von Actinomy-
cetales umfasst, gesucht. Dafür wurde ein bisher einzigartiges Wachstumssystem entwickelt, 
dass die zeitgleiche Kultivierung von bis zu 96 Stämmen von Actinomycetales auf Agar in einer 
Mikrotiterplatte erlaubt. Darüber hinaus ermöglichen die eigens dafür konstruierten Stempel-
platten die Übertragung der Stämme als Agar Blöcke, in Petrischalen um mit ihnen Agardiffu-
sionstests gegen unterschiedlichste Zielorganismen durchzuführen. Im Zuge dessen wurde die 
Tübinger Stammsammlung gegen den Monitorstamm Staphylococcus aureus PC322 gescreent. 
Dieser Stamm zeigt sowohl Verbindungen an, die mit dem agr System von S. aureus PC322 
interagieren, welches u.a. an der Regulation des Quorum sensing beteiligt ist, als auch solche, 
die das Wachstum von S. aureus PC322 hemmen. Innerhalb dieses Screenings wurden 
82 Stämme identifiziert, die mit dem agr System interagierten, sowie 284 Stämme, die das 
Wachstum von S. aureus PC322 inhibierten. Die jeweils vielversprechendsten Stämme wurden 
daraufhin hinsichtlich der für die Bioaktivität verantwortlichen Verbindungen untersucht. 
Der Stamm Streptomyces sp. Tü2700 zeigte in den Agardiffusionstests eine starke Interaktion 
mit dem agr System von S. aureus PC322. Mit Hilfe mehrerer chromatographischer und spekt-
roskopischer Verfahren konnte die Aktivität auf das bekannte Oxazol-polyene-γ-lactam/β-lac-
ton Antibiotikum Oxazolomycin A zurückgeführt werden. Die beobachtete Aktivität resultiert 
dabei weniger aus einer Interaktion mit dem agr System, als vielmehr aus einer sublethalen 
Inhibition von S. aureus, was einen Phänotyp des Monitorstamms ergibt, der dem einer echter 
Inhibition des agr Systems sehr ähnelt.  
Der Stamm Streptomyces sp. Tü2401 zeigte eine intensive Hemmung des Wachstums von  
S. aureus PC322. Abhängig von den Kultivierungsbedingungen von Streptomyces sp. Tü2401 
wurden unterschiedliche Substanzen isoliert und identifiziert, die für dessen Bioaktivität ver-
antwortlich sind. Kultivierung auf Agar führte zur Biosynthese des stark zytotoxischen Endiins 
C-1027. Diese Verbindung befindet sich derzeit in klinischen Studien zur Behandlung von Le-
berzellkarzinomen. 
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Die Entwicklung spezieller Aufreinigungsmethoden führte zur Identifizierung der, in submers 
Kultivierung von Streptomyces sp. Tü2401 produzierten, stark hydrophilen Sideromycine Albo-
mycin δ1 und δ2. Untersuchungen konnten deren außerordentliche Bioaktivität auch gegen 
multiresistente Gram-negative Bakterien belegen, bei gleichzeitigem günstigem toxikologi-
schem Profil in in-vivo Studien, was sie zu vielversprechenden Wirkstoffkandidaten macht. 
Aufgrund seines vielseitigen Biosynthesepotentials ist der Stamm S. sp. Tü2401 ein attraktiver 
Organismus für zukünftige biotechnologische Optimierungen hinsichtlich der Ausbeute, sowie 
der Erzeugung von Derivaten mit veränderter Wirksamkeit und Toxizität. 
Im Rahmen dieser Arbeit ist es zudem gelungen aus Streptomyces sp. AcE210 Xanthocidin und 
sechs weitere, bisher unbekannte Derivate mit Hilfe von Flash Chromatographie, SPE und se-
mipräparativer HPLC zu isolieren. Deren Strukturen wurden mittels HRMS, NMR, Polarimetrie 
und VCD-Spektroskopie aufgeklärt. Bei den Verbindungen handelt es sich um Dihydroxanthoci-
din, Homoxanthocidin, Xanthocidin B, Homoxanthocidin B, Xanthocidin C und Homoxanthoci-
din C. Aufgrund der strukturellen Analogie der Xanthocidine zu Methylenomycin A, B, und C 
konnte erstmals eine Hypothese für die Xanthocidin Biosynthese entwickelt werden. Laut die-
ser verläuft die Biosynthese ähnlich der von Methylenomycin. Der entscheidende Unterschied 
ist die Substratspezifität der, dem MmyC entsprechenden, KASIII in Streptomyces sp. AcE210 
für verzweigte Startereinheiten wie Isobutyryl-CoA oder 2-Methylbutyryl-CoA. Fütterungsex-
perimente mit Isotopen markiertem [13C5]-L-Valin zeigten den Einbau von Isobutyryl-CoA, wel-
ches ein Abbauprodukt von L-Valin ist, in das Xanthocidin Gerüst. Zudem konnte innerhalb der 
Genomsequenz von Streptomyces sp. AcE210 ein Cluster mit Homologien zu den an der Me-
thylenomycin Biosynthese beteiligten mmy Genen identifiziert werden.  
3          A Zusammenfassung
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B Summary 
The phylum of Actinobacteria is well known for its ability to produce a variety of bioactive 
compounds with various areas of application. Thus, within this thesis, the Tübingen strain col-
lection, which currently comprises more than 1000 selected Actinobacteria strains, has been 
chosen as a biological source for the discovery of new natural products. In order to facilitate a 
time and space efficient cultivation of the strains, a unique tool was developed, allowing for 
the contemporaneous cultivation of 96 strains on agar in stainless steel microtiter plates. 
Moreover, the custom-built plungers enabled the transfer of the strains as agar blocks into 
petri dishes, for subsequent agar diffusion assays comprising different target organisms and 
various bioactivity read-outs. As a proof of concept, the Tübingen strain collection was 
screened against the monitor strain Staphylococcus aureus PC322 which has been developed 
to identify compounds that interfere with agr, a key player of quorum sensing (QS) signal trans-
duction. 
Within the screening, 82 strains showed QS inhibition activity, while 284 strains exhibited an-
tibacterial activity. Two of the most promising strains from the screening have been analysed 
in regard to their bioactive compounds with Streptomyces sp. Tü2700 exhibiting QS inhibition 
activity, and Streptomyces sp. Tü2401 showing antibacterial activity.  
By various chromatographic and spectroscopic techniques, the oxazole polyene γ-lactam/ 
β-lactone antibiotic oxazolomycin A was identified as the bioactive compound produced by 
Streptomyces. sp. Tü2700. However, instead of a specific interaction with the agr system, the 
bioactivity is rather based on a sublethal inhibition of S. aureus PC322, both resulting in similar 
phenotypes of the monitor strain. 
Characterization of Streptomyces. sp. Tü2401 revealed that this strain was able to produce two 
different compounds depending on the cultivation conditions. On agar, the highly antibacterial 
and cytotoxic compound C-1027 was produced. which is currently being tested as new drug 
candidate against heptoma in phase II clinical trials. 
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The development of a specific purification procedure led to the identification of the hydro-
philic sideromycins albomycin δ1 and δ2, which were produced in submerse cultures of Strep-
tomyces. sp. Tü2401. Detailed characterization revealed their great potential especially against 
multi resistant Gram–negative, bacteria, while being at the same time well tolerated in in-vivo 
studies. In current times where multi resistant strains are on the rise, and antibiotics active 
against Gram–negative bacteria are scarce, albomycins are promising drug candidates. 
Within the course of this thesis, xanthocidin and six new derivatives were identified from the 
endophytic Streptomyces sp. AcE210 using flash chromatography, SPE and semi preparative 
HPLC. The structure of dihydroxanthocidin, homoxanthocidin, xanthocidin B, homoxantho-
cidin B, xanthocidin C and homoxanthocidin C were elucidated by HRMS, NMR, polarimetry 
and VCD spectroscopy. The structural resemblance of the xanthocidins to methylenomy-
cin A, B, and C, led to a hypothesis for the xanthocidin biosynthesis, which is similar to the 
biosynthesis of methylenomycin. The decisive difference is the substrate specificity for 
branched chain starter units such as isobutyryl-CoA or 2-methylbutyryl-CoA of the MmyC-cor-
responding KASIII in Streptomyces sp. AcE210. Isobutyryl-CoA is a degradation product of 
L-valine. Feeding studies with isotopically labelled [13C5]-L-valine confirmed that Streptomy-
ces sp. AcE210 incorporates an isobutyryl-CoA starter unit, resulting in a branched side chain 
in xanthocidin. Moreover, analysis of the genome sequence of Streptomyces sp. AcE210 re-
vealed a cluster of homologues to the mmy genes involved in methylenomycin biosynthesis.  
5              B Summary
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1. Introduction 
1.1 Natural products as lead structures for drug development 
The human evolution has always been closely connected to the use of natural goods to cover 
basic needs such as shelter, clothes, and food, but also for more advanced applications like 
spices, dyes, and also remedies. Sumerian clay tablets inscribed in cuneiform from ~ 2600 BC 
represent the first records of the medical application of plants, describing approximately 
1000 plant-derived drugs.1 Among these are oils of Glycyrrhiza glabra, Papaver somniferum, 
and Aloe barbadensis as remedies for respiratory tract infections, pain, diarrhea or 
constipations.2 Up to now, the monographs of these plans are an important part of European 
pharmaceutical codices. Other examples of ancient descriptions of phytopharmaceutical prod-
ucts include the Egyptian “Ebers Papyrus” from around 1500 BC, the Chinese “Wushi'er Bing-
fang” from around 1100 BC; the Indian “Charaka Samhita” from about 100 BC, and the ancient 
Greek “History of Plants” from about 300 BC.2–6 All these prequels of the modern pharmaco-
peia share the common fact that either the plant itself or a sort of plant extract is administered. 
In 1802, the German pharmacist Friedrich Wilhelm Adam Sertürner was the first to isolate a 
pure compound from opium, which is the dried latex obtained from Papaver somniferum. He 
termed this soporific, crystalline product “morphium”, after the Greek god of dreams, Mor-
pheus.7,8 Soon after, in 1827, the Prussian Government triggered the industrial production of 
drugs, which could be otherwise only obtained by time consuming processes, by allowing phy-
sicians and pharmacists in Germany to acquire drugs from factories.9 The pharmacist Heinrich 
Emanuel Merck can be considered as the first one producing and selling a pure natural product 
(NP), morphium, in an industrial scale.10,11 With the improvement in general manufacturing 
processes, semi-synthetic drugs have been introduced into the market, as well. The first com-
mercially available derivative of a natural product was acetylsalicylic acid, being sold by Bayer 
under the name “Aspirin®” since 1899.2,12 These findings in the late 18th /early 19th century 
started the intensive research on natural products. 
One key factor to the fascination of NPs comes from their chemical diversity and complexity. 
Their molecular weights range from small molecules with only a few Dalton (e.g. coumarin 
with 146 Da) to large biopolymers featuring serveral thousand Dalton (e.g. chitosan, ap-
prox. 322 kDa). In contrast to synthetic compounds, many NPs possess a considerable number 
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of asymmetric carbons.13 Studies of the relationship between the stereochemistry and the bi-
oactivity of various compounds revealed that only certain stereoisomers were able to trigger 
a biological response.14 Therefore, their stereochemistry, optimized throughout evolution, 
might be one reason why the number of NPs with bioactivity is significantly higher (0,6 %) 
compared to the number of synthetic bioactive compounds (0,005 %).15 However, it should be 
noted that the 1000-fold difference might also arise from the fact that NPs are mostly discov-
ered in bioactivity screenings aiming for the identification of bioactive compounds whereas 
the whole of synthetic compounds is not only derived from various, non-medicinal fields, in-
cluding the automobile or packaging industries, but also the creation of big compound librar-
ies. 
Up to now, around 250 000 NPs with bioactive or other useful characteristics have been iden-
tified covering multiple classes from antimicrobials, antivirals, cytotoxic and immunosuppres-
sive compounds to antidiabetics, enzyme inhibitors, nutraceuticals, polymers, surfactants, 
herbicides and even vaccines.16,17 Furthermore, among the 1211 small molecule drugs ap-
proved by the U.S. Food and Drug Administration (FDA) from 1981 to 2014, 65 % were native 
NPs, NP mimics or compounds with a NP-derived pharmacophore.18 However, the numbers 
vary depending on the fields of application. For instance, the main medical use of NPs consists 
in the treatment of infectious diseases and cancer with up to 78 % of the drugs being NPs.16 
The significance of NPs in drug development is also reflected in the ratio of NPs among the 
25 best-selling drugs in 1997 - 42 % of these were NPs or NP derived drugs. It is an incontro-
vertible fact that the market has changed within the last 20 years and monoclonal antibodies 
have become more important therapeuticals.18,19 This might explain why, within the 10 best-
selling drugs in 2017 no NPs were present but instead five of these were monoclonal antibod-
ies.20 These drugs are advantageous in certain indications like autoimmune diseases or cancer, 
since they are specific for one antigenic target and less prone for side effects.21 However, NPs 
still play an important role in drug development, since approx. 25 % of all by the U.S. FDA newly 
approved drugs in 2015 were NPs or NP derived.18  
Whereas in the past, the higher plants had served as main sources for bioactve NPs, the dis-
covery of penicillin by Fleming in 1928 revealed a new, important class of potential producers: 
microorganisms.22 Still, about 60 % of all bioactive NPs identified today are derived from 
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plants. The remaining 40 % is mostly produced by microorganisms, with only a few compounds 
coming from animal sources (e.g. Casein, Chitosan, Collagen, steroid hormones).16,23,24  
According to the dictionary of natural products (version 27.2), around 44 000 NPs from micro-
organisms are known to date. Of these, 50 % are produced by fungi and about ~23 % by fila-
mentous bacteria – more specifically the phylum Actinobacteria.25  
1.2 The importance of Actinobacteria in the identification of new bioactive NPs 
The Actinobacteria constitute one of the most species-rich, diverse phylum within the domain 
of bacteria.26 They are Gram-positive, filamentous bacteria, which are widely distributed in 
terrestrial and aquatic as well as marine eco systems.27 Actinomycetes possess several distinc-
tive features, including a high Guanin and Cytosin content in their genomic DNA, a mycelial life 
cycle, and the ability to undergo a complex morphological differentiation. Their typical type of 
growth, characterized by a unique combination of branching of the hyphae and tip extension, 
gave them their name, which is the combination of the Greek words for ray (aktis or aktin) and 
fungi (mukes).28 In addition to their characteristic life cycle, Actinobacteria exhibit an extensive 
secondary metabolism, leading to the production of many different compounds by one single 
strain, depending on growth conditions and sampling time.29,30 
The phylum of Actinobacteria comprises various families ranging from Corynebacteriaceae, 
Mycobacteriaceae, Nocardiaceae to Micromonosporaceae and Streptomycetaceae. While the 
first three include pathogenic species, Micromonosporaceae, and Streptomycetaceae are 
more famous for their ability to produce a wide range of secondary metabolites, including but 
not limited to antibiotics, anticancer or immunosuppressive drugs, which all have a great in-
fluence on our daily life.28,31,32 Especially the family of Streptomycetaceae comprises the argu-
ably largest antibiotic-producing genus, namely Streptomyces, which is responsible for the pro-
duction of 80 % of the clinically used antibiotics.33,34 American Nobel laureate (1952) Selman 
Abraham Waksman became the first scientist to discover an antibiotic from the genus Strep-
tomyces. He managed to isolate actinomycin from Streptomyces antibioticus at Rudgers Uni-
versity, USA, in 1940.35,36 However, it took four additional years and the discovery of strepto-
mycin from Streptomyces griseus before a more systematic screening for bioactive compounds 
in this genus was initiated.37–40 
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In general, more than half of the antibiotics in clinical use are produced by the phylum of Ac-
tinobacteria including β-lactams, tetracyclins, rifamycins, aminoglycosides, macrolides and gly-
copeptides.16,41,42 
Furthermore, the significance of Actinobacteria can also be attributed to their ability to pro-
duce a variety of other bioactive compounds, such as herbicides, insecticides, antifungals, an-
tivirals, antitumor and immunosuppressive drugs, antiparasitic, as well as anthelmintic 
agents.28,43 Nevertheless, it has become progressively difficult to obtain novel compounds. 
Limitations in culturing methods combined with high rates of rediscovery of already known 
compounds have significantly hampered our current drug screening efforts. This is also re-
flected in a 30 % decrease in NP-based drugs entering clinical studies from 2001 to 2008.44,45 
However, whole genome sequencing and genome mining have revealed that most strains har-
bour more biosynthetic gene clusters than already identified compounds.46 Smanski et al. have 
estimated that the genus Streptomyces might be able to produce more than 150 000 second-
ary metabolites, of which approximately 5% are known so far.47 In order to access so-called 
“silent” or “cryptic” gene clusters, two strategies are currently applied. First, empirical optimi-
sation of the growth conditions, addition of chemical elicitors (e.g. trace metal ions) to the 
production medium, ribosome engineering and optimisation of regulatory genes are all useful 
methods applied in the past to target the cryptic gene cluster.45,48–51 Secondly, it has been 
shown that the identification and exploitation of new non-streptomycetes and novel Strepto-
myces strains also can lead to the discovery of new NPs.52,53 As a result, until 2005 approxi-
mately 2250 new bioactive natural products have been discovered from so called “rare” acti-
nomycetes like e.g. Micromonospora, Nocardia, Actinomadura, Actinoplanes, Streptover-
ticilllium and Saccharopolyspora e.g. abyssomycin and proximicin from Verrucosispora ma-
ris.45,54–57 
Despite recent progresses in cultivation techniques, the majority of bacterial strains is still con-
sidered to be unculturable. According to 16S rRNA analysis, it has been estimated that to date 
only 1 % of the bacteria can be cultured under laboratory conditions.45,58 Therefore, methods 
and concepts have been and are currently being developed to exploit this “dark matter”.58 One 
approach that has already been employed for the discovery of new NPs focuses on the screen-
ing of large metagenomic libraries.45,59 For this purpose, environmental DNA (eDNA), obtained 
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from environmental samples is transferred into a heterologous host. Using this culture-inde-
pendent approach resulted in the identification of malacidins, a novel class of antibacterials 
targeting lipid II, a cell wall precursor, that, in a complex with calcium, leads to the destruction 
of the cell wall.60  
Taken together, these examples show that, despite current limitations, the discovery of new 
NP from Actinobacteria is still a promising, not yet exhausted field of research.41,45   
1.3 Anti-infectives 
Any drug capable of inhibiting infectious disease is termed anti-infective, encompassing anti-
fungals, anthelmintics, antimalarials, antiprotozoals, antituberculosis agents, antivirals, and 
antibiotics. The term antibiotic was coined in 1947 by Selman Waksman as follows: “An anti-
biotic is a chemical substance, produced by micro-organisms, which has the capacity to inhibit 
the growth of and even to destroy bacteria and other micro-organisms.”61 This definition has 
later been broadened in order to include also those antibacterial compounds of solely syn-
thetic origin as well, e.g. quinolone antibiotics.62   
The so-called antibacterial era was initiated by the two German scientists Alfred Bertheim and 
Paul Ehrlich, who discovered what can be considered being the first synthetic antibacterial 
compound in 1907. Arsphenamin, also known as salvarsan, a cyclopolyarsenin, was used as 
remedy for syphilis.63,64  
However, it was Sir Alexander Fleming, who, by his serendipitous discovery of penicillin in 
1928, kicked off the extensive research on antibacterial drugs for the following decades.22 Dur-
ing this so-called golden era of antibacterial drug discovery, most of the antibiotic classes 
known today, came into clinical use such as e.g. the aminoglycosides (1944), tetracyclines 
(1950), and macrolides (1952).62,65  
During this time, several research groups and companies initiated their efforts to establish 
strain collections to improve discovery of novel, NP-based drug leads. Some of these groups 
carrying out systematic screenings of bacterial strain collections include that of Selman Waks-
man in the United States, in Europe by Hans Zähner at the University of Tübingen and in Japan 
by Hamao Umezawa at the Institute for Antibiotics in Tokyo and Satoshi Omura at the Kitasato 
University in Tokyo. Their combined efforts led to the discovery of more than 1000 new NP, 
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including several antibiotics, like kanamycin, josamycin, several erythromycin derivatives and 
other macrolide antibiotics.13 However, the efficacy of those screening pipelines dropped in 
the early 1960s.66 As a result, no new class of antibiotics, except for the carbapenems, was 
discovered between the early 1960s and 2000. During this time, instead of isolating new com-
pounds, the development shifted towards the modification of existing scaffolds in order to 
improve pharmacological properties or to overcome resistances.29,67 Hence, almost all antibi-
otics approved by the FDA during this time were derivatives of known compounds.68 Due to 
the successful and global application of antibiotics, mortality rates of previously life-threaten-
ing bacterial diseases dropped substantially. While infectious diseases used to be the main 
cause of death worldwide in the 1900s, it has been the second-leading in the world 100 years 
later, respectively the third-leading in developed countries.69,70 Several examples exist to high-
light the impact of anti-infectives on global health. One of these is the reduction of the mor-
tality rate of acute meningococcal meningitis from 70–90 % in the pre-antibiotic era to ~ 10 % 
after subcutaneous sulfanilamide injections began to be employed as treatment.⁠71 
Unfortunately, blinded by their successes, people began to forget the original warnings of Sir 
Alexander Flemings, who, in his Nobel prize lecture in 1945, mentioned that “it is not difficult 
to make microbes resistant”.72 Hence, during the following decades, antibiotic therapy was 
further expanded not only in human therapies, but also in animal medicine and farming. This 
misuse combined with the increased mobility of people in a more globalized world and in-
creased industrialisation have led to the evolution and spread of resistant bacteria.73 Some 
pathogenic bacteria have even acquired resistances against multiple antibiotics and, as a re-
sult, are referred to as multiresistant pathogens or even “superbugs”. As a consequence of the 
rise of resistance, the failure of antibiotic therapies has already increased morbidity and mor-
tality and additionally puts an economic burden on the public health systems.74 
During the same period of time the number of antibacterial drugs, which were newly approved 
by the FDA, decreased from 2.9 per year in 1960 to 1.6 per year in 2000. ⁠71 The reasons for this 
decline are many, one of the more important being the decreased efforts of the major phar-
maceutical companies in research on anti-infectives. Here, especially the expenses associated 
with the development of new drugs, which have been estimated to be around 1 billion US$, 
have limited the company’s interest in this field.75 Instead, many companies shifted their focus 
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towards chronical diseases, which promise better margins.76 As a result, only four major phar-
maceutical companies pursued research on antibiotics in 2010, namely AstraZeneca (London, 
UK), Novartis (Basel, Switzerland), GSK (London, UK) and Sanofi (Paris, France) whereas, 
20 years earlier, the number was 18.77 
Ultimately, these opposing trends have provoked a growing fear of the occurrence of  
non-treatable “superbugs” and the return to the pre-antibiotic era.⁠78 In order to combat this, 
it is essential to develop new anti-infectives with properties that can aid in overcoming existing 
resistances and at the same time being less prone to develop new ones.79    
However, the concerted efforts of researchers, companies and governments led to the discov-
ery of 25 new antibacterial drugs, which have been approved by the FDA in the time between 
2000 to 2015.80,81 Most of these are derivatives of known ones, but five represent members 
of new antibiotic classes: Linezolid (oxazolidinone), daptomycin (lipopeptide), retapamulin 
(pleuromutilin), fidaxomicin (tiacumicin) and bedaquiline (diarylquinoline).77,80 
Unfortunately, one major limitation of all of these new classes are the lack of activity against 
gram-negative bacteria. Gram-negative bacteria represent the majority of antibiotic-resistant 
bacteria. The Infectious Diseases Society of America (IDSA) has highlighted six pathogens as 
so-called “ESKAPE” organisms (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneu-
moniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacteriacea), of which 
five are gram negative. They are the clinically most relevant pathogens as they have developed 
resistances allowing them to “escape” most of the common antibacterial therapies including 
the drug of last resort vancomycin.82 Following the IDSA, the WHO has named Acinetobac-
ter baumannii, Pseudomonas aeruginosa, Enterobacteriacea and Staphylococcus aureus 
among others as the most problematic pathogens for which new antibiotics are urgently 
needed.83 
Although the research dealing with discovery of new anti-infectives is on the right track, there 
is still an urgent need for the development of new strategies to overcome resistances. 
1.3.1 Strategies to overcome resistances – Antivirulence concept 
Concepts to overcome antibiotic resistances are as diverse as the resistance mechanisms de-
veloped by pathogens. One example is the combination of a drug which is susceptible to efflux 
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or enzymatic degradation with an efflux pump or enzyme inhibitor.84–86 Additionally, the en-
hancement of binding affinity of the drug towards the target or the reduction of side effects 
by structural optimization of the anti-infective compound are examples of two very distin-
guished approaches for a higher efficacy.87 Furthermore, as mentioned above, the develop-
ment/discovery of novel antibiotic classes remains an important research topic as well as the 
identification of novel drug targets.88 However, what all these approaches have in common is 
that they are targeting bacterial compartments or functions that are crucial for survival or pro-
liferation of the pathogen. Therefore, these approaches still bear the risk of provoking new 
resistances due to selection pressure in the pathogens.⁠78 
A promising approach to overcome the obstacle of selection pressure in pathogen presents 
itself with the anti-virulence concept in which neither cell viability nor bacterial fitness are 
targeted, but rather virulence-associated mechanisms.86,89–91 Hence, this approach aims at dis-
arming pathogens and thereby enabling the host’s immune system to effectively clear the 
pathogen by itself having little to no impact on the native human microbiota.86,91 Since these 
so-called patho- or virulence blockers ideally should not interfere with bacterial growth (bac-
teriostatic) or viability (bactericidal), the selective pressure is alleviated.91 Thereby, it has been 
assumed, that those drugs possess a reduced likelihood for the emergence of resistance rela-
tive to current antibiotics.86,92–97 However, this remains to be verified empirically.91  
Factors or mechanisms crucial for the initiation of infections or for causing diseases are prom-
ising, potential targets for the development of antivirulence therapies. More specifically, these 
include pathogenicity factors promoting cell adhesion, cell invasion, mechanisms to evade or 
overcome host immune defence, intracellular replication and damage of host tissues, stress 
adaptation and metabolic functions important to adapt to the different host environments, 
biofilm formation as well as maintenance, and control systems regulating the expression of 
virulence-relevant genes.86 Especially these approaches seem promising for the development 
of new anti-infective drugs, that target classical virulence factors, such as adhesins/invasins, 
which inhibit pathogen-induced host signalling disruption by toxins, effectors, and immune 
modulators, manipulating microbial signal transduction and regulation, or interfere with func-
tions required for bacterial survival and/or persistence during the infection.86 
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Interfering with bacterial cell-to-cell communication, also referred to as quorum sensing (QS), 
has been found to be a promising way to disrupt bacterial virulence.90,98–104 The term “quorum 
sensing” is used to describe intercellular communication systems which allow bacteria to sense 
their direct environment in order to examine their particular cell density.105–107 The communi-
cation system relies on small molecules, which are constantly synthesized and secreted. The 
small molecules are recognized by the surrounding bacteria via cognate receptors present ei-
ther on the surface of the bacterial cells (Gram-positive bacteria) or in the intracellular matrix 
(Gram-negative bacteria).105–109 When a certain threshold concentration is reached, gene ex-
pression in the respective bacteria changes, and they start to behave as multicellular organ-
isms, producing for example biofilms or virulence factors. Since inhibition of these systems can 
lower the virulence of pathogenic microorganisms without affecting their growth, they are 
seen as promising leads for new anti-infectives, since emergence of resistance is less prone to 
happen.110–113 Unfortunately, as shown for Pseudomonas aeruginosa, the potency of quorum 
sensing inhibitors (QSI) is influenced by the presence of active efflux mechanisms.114 There are 
several possibilities to inhibit QS, including (l) lowering the activity of the autoinducer synthase 
and thereby reducing the production of signal molecules, or (II) through degradation of the 
autoinducer, or (III) by allosterically or competitively blocking the respective signal recep-
tors.90,110,115  
Although extensive research on quorum sensing inhibition (QSI) has been carried out in recent 
years and several QS-inhibiting compounds have been identified, such as hamamelitannin, 
furanone C-30, or fimbrolide (F1), none of them has yet entered the market, due to critical 
side effects or reduced activity in animal studies.115–117 
1.3.2 The QS networks of S. aureus 
Staphylococcus aureus is a Gram-positive, facultative anaerobic, coccus-shaped bacterium.118 
It is a at the same time a commensal bacterium, colonizing approximately 30 % of the human 
population, and at the same time a human pathogen.119 Since it has the potential to cause a 
variety of infections, including bacteremia, skin and soft tissue infections, infective endocardi-
tis, pleuropulmonary, device-related infections and osteomyelitis, S. aureus is considered to 
be the leading cause of nosocomial infections worldwide.118,120–122 
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For decades, β-lactam antibiotics such as penicillin have been used as the classical course of 
treatment for S. aureus infections. However, already in 1950, approximately 40 % of all S. au-
reus hospital isolates were penicillin-resistant. Only ten years later, in 1960, this number rose 
up to 80 %.123 This stunning increase in spread of resistances is most likely due to natural se-
lection or horizontal gene transfer. With the emergence of strains having acquired resistances 
to multiple β-lactam antibiotics, including the penicillin-derivative methicillin, the treatment 
of Staphylococcus infections has become increasingly challenging.124 Glycopeptides such as 
teicoplanin and vancomycin are currently the first-line treatments for serious, invasive methi-
cillin-resistant S. aureus (MRSA) infections.124 However, the first cases of vancomycin-resistant 
S. aureus (VRSA) were already reported in 2002.125 
S. aureus employs a biphasic strategy for invasion and infection. At low cell densities, the bac-
teria express protein factors for attachment and colonization such as Protein A encoded by the 
gene spa. However, at high cell densities these pathways are suppressed in order to initiate 
secretion of toxins such as α-hemolysin encoded by hla, and proteases, which are most likely 
necessary for dissemination.106,126–128 For the regulation of virulence, S. aureus uses at least 
two different QS systems: The agr system and the RAP/TRAP system.120,129 These two circuits 
employ on one hand cyclic peptides, the so-called autoinducing peptides (AIP) and on the 
other hand the RNAIII-activating protein (RAP).120,130 
Although three AIP families are known, Staphylococcus spp. only uses AIP of the thiolactone 
class. Within this class, four different groups can be distinguished based on the amino acid 
sequence in S. aureus.120 After posttranslational modification, the functional AIP can only in-
duce its own agr expression. Furthermore, AIP of one group can even act as inhibitors for other 
groups.131 In addition to this, structure-activity relationship studies have revealed that the tail 
of the AIP is necessary for the activation of the agr system whereas the macrocycle is respon-
sible for antagonistic activity, which has led to the synthesis of truncated AIPs.127,129,132,133 
The cognate receptors of the AIPs are transmembrane histidine protein kinase receptors called 
AgrC. They consist of a N-terminal transmembrane sensor domain, which is highly variable, 
and a conserved C-terminal histidine protein kinase domain.134 After activation by the respec-
tive AIP, it has been speculated that AgrC, like other histidine protein kinases, forms a dimer 
and undergoes autophosphorylation followed by the transfer of one phosphoryl group to the 
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response regulator AgrA.120,135 In turn, the phosphorylated AgrA activates the transcription of 
the two promoters P2 and P3, completing a positive feedback loop.129,136 The P2 transcripts 
are responsible for the activation of the agrBDCA operon, whose gene products are responsi-
ble for the production, export, and import of AIP.129 The transmembrane endopeptidase AgrB 
processes the propeptide AgrD by cleaving segments from the C-terminal end followed by a 
condensation between the cysteine residue and a C-terminal carboxyl group resulting in the 
typical thiolactone ring.137 P3 is the promoter region of a RNAIII encoding gene.120 120 Besides 
encoding the 26 amino acid peptide δ-hemolysin, which is presumably involved in biofilm in-
tegrity, the regulatory RNA RNA-III downregulates the transcription of genes involved in adhe-
sion (e.g. spa) and activates the transcription of virulence genes encoding for example hemo-
lysins (hla), Panton-Valentin leucocidin, and enterotoxins (see Figure 1).120,131,135 
The second signalling molecule employed by S. aureus in QS is RAP.138 Not much is known 
about this QS circuit, neither about its synthesis nor its secretion. It has been speculated that 
RAP binds to the cognate receptor TRAP after a certain extracellular threshold has been 
reached resulting in the phosphorylation of the latter. Subsequently, the agr system and 
thereby RNA-III transcription is activated. Nonetheless, the role of RAP in QS is still part of a 
lively discussion.120 This is also why it is still uncertain whether RAP really operates as a second 
QS signal in S. aureus.120,139,140   
The presence of a third QS circuit in S. aureus, which employs autoinducer-2 (AI-2), is currently 
under discussion. Genes encoding the metalloenzyme LuxS, which is the key enzyme in the 
production of AI-2, a mixture of signalling molecules originating from 4-,5-dihydroxy-2,3-pen-
tanedione (DPD), are widely conserved in both gram-negative and gram-positive bacteria in-
cluding in S. aureus.120,141,142 However, genomic analysis has also revealed that the cognate 
receptor LuxR is not present in Staphylococcus ssp.143 Additionally, the exact structure of active 
DPD in Staphylococcus spp. is still unknown. Although it has been demonstrated that 
LuxS/AI-2 can regulate cellular functions in S. aureus through the KdpDE two-component sys-
tem, the exact mechanisms of interaction are still unknown.144,145 Thus, it remains uncertain 
whether S. aureus can employ AI-2 as signalling molecule.120,144,146 
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Figure 1. Schematic figure of the agr quorum sensing system in S. aureus. Autoinducing pep-
tides (AIP, green) acts on the N-terminal transmembrane sensor domain of AgrC, inducing autophos-
phorylation followed by the transfer of one phosphoryl group to the response regulator AgrA. Phos-
phorylated AgrA activates the transcription of the two promoters P2 and P3. P2 is completing a positive 
feedback loop by activating the agrBDCA operon, whose gene products lead to the production, export, 
and import of AIP. The P3 promoter controls the transcription of the regulatory RNA RNA-III, directing 
the upregulation of virulence genes, as well as the downregulation of genes involved in adhesion  
(e.g. spa). Heterologous, non-cognate AIP can act as inhibitors of the system, when competing with 
cognate AIP for AgrC receptor binding. (adapted from Novick et al.)135  
Finally, in order to identify new QS inhibitors, Nielsen et al. developed a screening assay based 
on S. aureus LacZ reporter fusion strains.147 This assay utilizes the agr regulated gene hla, 
which is fused with LacZ. Upon activation, AgrC leads the expression of hla as well as of lacZ, 
which encodes for a β-galactosidase. That in turn can be detected by the occurrence of a blue 
colour, resulting from the cleavage of 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside 
(X-Gal) mediated by the β-galactosidase.147 Hence, compounds interfering with S. aureus QS 
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will result in an unstained, hazy zone of inhibition. Accordingly, this assay has led to the iden-
tification of several NPs interfering with the agr system, e.g. norlichexanthron or solo-
namides A and B.147–149 The first one is a small non-reduced tricyclic polyketide, which is pro-
duced by lichen or fungi. It has been shown that norlichexanthron binds to AgrA and thus 
blocks its ability to bind at the promoter regions P2 and P3, leading to a reduced expression of 
RNA III and hla.148 The solonamides A and B are cyclodepsipeptides that have been isolated 
from the marine bacterium Photobacterium halotolerans. Due to their structural resemblance 
with the natural S. aureus AIP’s they act as competitive inhibitors and interfere with the bind-
ing of the AIP to the sensor histidine kinase, AgrC (see Figure 1; red AIP), which leads to signif-
icant reduction of the expression of RNA III and hla.149,150  
1.4 Phenotypic screening approach 
Within the last century, scientists and companies have used mainly two different approaches 
to test fermentation broths, extracts or pure compounds for identifying new bioactive com-
pounds: Phenotypic or target based screenings.151 The latter have been the main focus of drug 
discovery in the past 20 years. The advancements in recombinant DNA technologies and the 
better understanding of biochemical processes have led to the development of many whole-
cell or biochemical assays. They do not only allow for the identification of the mode of action 
(MoA) of a drug of interest but also feature an enormous throughput and the whole screening 
process became more rational.13,152–154 Thus, by modulating the targets activity, the whole 
screening process became more rational. However, the modulation of a certain targets activity 
may either not be of relevance for the disease pathogenicity or the responsible compounds 
may have an insufficient therapeutic index.155 Although some companies, such as Roche’s 
Genetech Inc., continue to employ the target-based approach for their drug discovery studies, 
other companies, including GlaxoSmithKline plc and Novartis AG, are investing more efforts in 
the classical phenotypic screening approach in order to overcome the limitations in the single-
target screenings.151  
The phenotypic screening is a target-independent approach, in which extracts or single com-
pounds are analysed, resulting in an appropriate phenotype supposedly associated with a ther-
apeutic effect.156 In contrast, the phenotypic screening enable the discovery of bioactive com-
pounds without having prior knowledge of their respective targets or MoA.13 Additionally, it 
has been shown that activities from phenotypic screenings can be translated into therapeutic 
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impact more effectively than those from the target based approaches.13 However, identifica-
tion of the target is even though often challenging and not always crowned with success, ben-
eficial for an approval of the new compound by the FDA. Mark Fishman, president of the No-
vartis Institutes for BioMedical Research, stated in 2012 that the pass rate for the target iden-
tification is “somewhere in the 40 % range”.151 Furthermore, in the process of preclinical and 
clinical development, it has been shown that substances with unknown targets are more chal-
lenging since the mechanism-related toxicities are more difficult to predict.151 In addition, also 
the optimisation of the molecular properties of the candidate drugs is often an ambitious 
problem as no prior knowledge of the structural features mandatory for activity exists. Another 
disadvantage of the phenotypic screening approach is the low time efficiency, in which some 
of the assays suffer from noticeably lower throughputs than the target-based assays.151,155 In 
the period between 1999 and 2008, 75 first-in-class drugs with new MoA were approved by 
the FDA. Of these, 50 compounds belonged to the class of small molecules and 25 were bio-
logicals. Interestingly, even though target-based approaches were more prominent during this 
time, 56 % of these drugs were discovered in phenotypic screenings and only 34 % by target-
based approaches.155 Worth noting is that these numbers vary depending on the therapeutic 
area. As an example, 63 % of the small molecule anti- cancer therapeutics were derived from 
target-based screening, whereas 70 % of the small molecule anti-infectives were derived from 
phenotypic screenings, e.g. daptomycin or retapamulin.155,157,158 In this regard, NPs are of sig-
nificant interest, since their structure, the target, and the MoA have already been optimized 
through evolution. As a consequence, the combination of the phenotypic screening for  
anti-infective substances with NPs is a promising approach for the identification of new candi-
date drugs.155  
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1.5 Aim of the Thesis  
The aim of this thesis was the identification of new natural products from the phylum Actino-
bacteria. For this purpose, the Tübingen strain collection, which currently comprises more than 
1000 selected Actinobacteria strains, has been chosen as a biological source for the discovery. 
Initially, a screening platform, allowing a fast and efficient growth and bioactivity testing of the 
whole strain collection needed to be developed. Subsequently, in order to identify new anti-
infective, or antivirulent natural products, the Tübingen strain collection was screened against 
the S. aureus PC322 assay that has been developed by Nielsen et al..147 This assay has been 
developed to identify compounds that interfere with the agr system of S. aureus, which has a 
key function in the regulation of QS in S. aureus. 
The biological active compounds of the most promising strains were isolated. Therefore, opti-
mal production conditions for the respective strains were identified. Additionally, extraction 
and isolation protocols for the individual compounds were developed using e.g. several chro-
matographic techniques.  
Finally, the biological active compounds were dereplicated and their structure elucidated with 
the help of techniques like MS and NMR. 
Additionally, the present work also aimed at the identification and characterisation of new 
natural products with rare structural features, independent from their bioactivity. Within this 
scope, Streptomyces sp AcE210 was analysed due to its potential to synthesise a rare cyclo-
pentanone antibiotic – xanthocidin.  
2.1 Chemicals & Instruments 31  
2. Material & Methods 
2.1 Chemicals & Instruments 
Table 1. Chemicals & solvents 
Chemical Vendor 
Aceton Sigma-Aldrich, St. Louis (USA) 
Acetonitrile (ACN) J. T. Baker® Avantor Performance Materials, Deventer (NLD) 
Acetonitrile-d3 Carl Roth GmbH & Co. KG, Karlsruhe (DE) 
Agar Carl Roth GmbH & Co. KG, Karlsruhe (DE) 
Ammonium formate Sigma -Aldrich, St. Louis (USA)  
Butanol Merck KGaA, Darmstadt (DE) 
Dichlormethane (DCM) Fisher Scientific, Loughborough (UK) 
Dimethylsulfoxid (DMSO) Merck KGaA, Darmstadt (DE) 
Dimethylsulfoxid-d6 Carl Roth GmbH & Co. KG, Karlsruhe (DE) 
Ethanol Sigma-Aldrich, St. Louis (USA) 
Ethyl formate Merck KGaA, Darmstadt (DE) 
Ethylacetat (EA) Sigma-Aldrich, St. Louis (USA) 
Formic acid (FA) Merck KGaA, Darmstadt (DE) 
Hamamelitannin  Carl Roth GmbH & Co. KG, Karlsruhe (DE) 
Hydrogen chloride (HCl) VWR International GmbH, Darmstadt (DE) 
Methanol (MeOH) Sigma -Aldrich, St. Louis (USA)  
Methanol-d4 Sigma-Aldrich, St. Louis (USA) 
Methyl acetate Merck KGaA, Darmstadt (DE) 
Sodium hydroxide (NaOH) VWR International GmbH, Darmstadt (DE) 
X-β-Gal  Carl Roth GmbH & Co. KG, Karlsruhe (DE) 
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Table 2. Components of HPLC systems 
System Specification Component 
Agilent 1200 Series  G1379B  Degasser 
 G1312A  Binary Pump 
 G1367B  Autosampler 
 G1330B  Thermostat 
 G1316A  Column Compartment 
  G1315B  Diode Array Detector 
Agilent 1260 Infinity  G4225A  Degasser 
  G1312C  Binary Pump 
  G1329B  Autosampler 
  G1330B  Thermostat 
  G1316A  Column Compartment 
  G1315D  Diode Array Detector 
  G1346C Fraction collector 
Agilent 6330 IonTrap    
Sedex LT-ELSD  Model 85LT ELSD 
2.2 Strain cultivation 
2.2.1 Media 
All media were prepared by dissolving the relevant ingredients (see Table 3) in MilliQ water 
and subsequent pH adjustment using NaOH or HCl, respectively. If not stated otherwise,  
2 % (w/v) agar (Sigma-Aldrich, St. Louis, USA) were added for solid media. All media were au-
toclaved at 121°C. 
Table 3. Compositions of media 
Name Substance Vendor Concentration pH 
KM4 Broth Yeast extract Ohly GmbH, Hamburg, D 4 g/l 7.3 
 Malt extract Thermo Fischer Scientific, Waltham, USA 10 g/l  
 Dextrose Carl Roth, Karlsruhe, D 4 g/l  
TS-Broth TSB Thermo Fischer Scientific, Waltham, USA 30 g/l 7.3 
TS-Agar TSA Becton, Dickinson and Company, Sparks, 
USA 
40 g/l 7.3 
LB LB-Broth Sigma-Aldrich, St. Louis, USA 20 g/l 7.3 
ISP2  Yeast extract Ohly GmbH, Hamburg, D 4 g/l 7.3 
 Malt extract Thermo Fischer Scientific, Waltham, USA 10 g/l  
  Dextrose Carl Roth, Karlsruhe, D 4 g/l   
ISP3/OM  Oatmeal Holo 
Hafergold 
Reform Kontor GmbH & Co.KG, Zarren-
tin, D 
20 g/l 7.3 
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Trace metal 
mix 
  5.0 ml  
Trace metal mix CaCl2 ·2H2O 
 N/A 
3 g/l  
 Iron(III)-citrate N/A 1 g/l  
 MnSO4 ·1H2O N/A 200 mg/l  
 ZnCl2 N/A 100 mg/l  
 CuSO4 ·5H2O N/A 25 mg/l  
 Na2B4O7 · 
10H2O 
N/A 20 mg/l  
 CoCl2 ·6H2O N/A 4 mg/l  
 Na2MoO4 ·2H2O  N/A 10 mg/l  
NL 19  Mannit Merck KGaA, Darmstadt (DE) 20 g/l 7.5 
  Soy meal Henselwerk, Magstadt (DE) 20 g/l   
NL 200  Mannit Merck KGaA, Darmstadt (DE) 20 g/l 7.5 
  Cornsteep 
powder 
Marcor Development Corporation, 
Carlstadt (USA) 
20 g/l   
NL 300  Mannit Merck KGaA, Darmstadt (DE) 20 g/l 7.5 
  Cotton seed 
powder 
PharmaMedia Dr. Müller GmbH, Leimen 
(DE) 
20 g/l   
NL 333  Dextrose Carl Roth GmbH & Co. KG, Karlsruhe (DE) 5  g/l 7.0 
 Starch, soluble Carl Roth GmbH & Co. KG, Karlsruhe (DE) 10 g/l  
 Malt extract Thermo Fischer Scientific, Waltham 
(USA) 
10 g/l  
 Yeast extract Carl Roth GmbH & Co. KG, Karlsruhe (DE) 3 g/l  
 BactoTM Pep-
tone 
Becton, Dickinson and Company, Sparks 
(USA) 
3 g/l  
 Ammoniumni-
trate 
Merck KGaA, Darmstadt (DE) 3 g/l  
  CaCO3 Merck KGaA, Darmstadt (DE) 2 g/l   
NL 400  Dextrose Carl Roth GmbH & Co. KG, Karlsruhe (DE) 10 g/l 7.0 
 Starch Carl Roth GmbH & Co. KG, Karlsruhe (DE) 2 g/l  
 BactoTM Pep-
tone 
Becton, Dickinson and Company, Sparks 
(USA) 
3 g/l  
 Yeast extract Carl Roth GmbH & Co. KG, Karlsruhe (DE) 5 g/l  
 Meat extract N/A 3 g/l  
  CaCO3 Merck KGaA, Darmstadt (DE) 3 g/l   
NL 410  Dextrose Carl Roth GmbH & Co. KG, Karlsruhe (DE) 10 g/l 7.0 
 Glycerol Sigma-Aldrich, St. Louis (USA) 10 g/l  
 Oat meal ReformKontor GmbH & Co. KG, Zarrentin 
(DE) 
5 g/l  
 Soy meal Henselwerk, Magstadt (DE) 10 g/l  
 Yeast extract Carl Roth GmbH & Co. KG, Karlsruhe (DE) 5 g/l  
 BactoTMCasami-
noacid 
Becton, Dickinson and Company, Sparks 
(USA) 
5 g/l  
  CaCO3 Merck KGaA, Damrstadt (DE) 1 g/l   
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NL 500  Starch, soluble Carl Roth GmbH & Co. KG, Karlsruhe (DE) 10 g/l 8.0 
 Dextrose Sigma-Aldrich, St. Louis (USA) 10 g/l  
 Glycerol Sigma-Aldrich, St. Louis (USA) 10 g/l  
 Fish meal Becton, Dickinson and Company, Sparks 
(USA) 
15 g/l  
  Sea salt Sigma-Aldrich, St. Louis (USA) 10 g/l   
KM5  Yeast extract Carl Roth GmbH & Co. KG, Karlsruhe (DE) 4 g/l 5.5 
 Malt extract Thermo Fischer Scientific, Waltham 
(USA) 
10 g/l  
 Dextrose Carl Roth GmbH & Co. KG, Karlsruhe (DE) 4 g/l  
2.2.2 E. coli K12, B. subtilis 168 & S. aureus PC322 
E. coli K12, B. subtilis 168 were cultivated in LB medium (K12 & 168) at 30 °C (168) or 37 °C 
(K12). S. aureus PC322 was cultivated in TSB, supplemented with 5 μg/ml erythromycin at 
37 °C. Strains were either grown in liquid cultures in flasks with baffles and spirals, and shaken 
at 180 rpm, or on solid media incubating statically. Pre-cultures were either inoculated with 
single colonies, grown on solid media or with 20 µl of a solution of cryopreserved spores. 
Pre-cultures were used to inoculate main cultures (1 % (v/v)). Main cultures were incubated 
for 16 h. 
2.2.3 Cultivation of Streptomyces sp. Tü2700 and Streptomyces sp. Tü2401 
Streptomyces sp. Tü2700 and Streptomyces sp. Tü2401 were incubated at 29 °C in miscellane-
ous complex media. Cultures grown on solid medium (ISP2 agar) were inoculated with 50 µl of 
a pre-culture and incubated until sporulation occurred (Tü2700: 7 d; Tü2401: 4 d). Submerse 
cultures were inoculated with 1 % (V/V) of pre-culture and incubated in Erlenmeyer flasks 
(max. 10 % media filling) equipped with baffle and spiral at 180 rpm.   
2.2.3.1 Preparation of Pre-cultures 
Pre-cultures of Streptomyces sp. Tü2700 and Streptomyces sp. Tü2401 were inoculated either 
with spores from the respective agar plates, or with 50 µL of the respective solution of cryo-
preserved spores. They were incubated in a 100 ml Erlenmeyer flask, filled with 20 ml of NL410 
medium for three days at 180 rpm. 
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2.2.3.2 Preparation of cryopreserved spores 
In order to maintain a long-term stock of each bacterial strain, spore suspensions with a final 
concentration of 37.5 % glycerol were prepared. The respective strains were grown on agar 
plates until sporulation occurred. The spores were collected by suspending in 5 ml sterile 
37.5 % glycerol in water (v/v). The cultures were stored in cryotubes at - 80 °C. 
2.2.4 Fermentation in the bioreactor 
Streptomyces sp. Tü2700 and Streptomyces sp. Tü2401 were cultivated at 27 °C each in a 
10 l bioreactor at a rotor speed of 200 rpm, and an airflow of 5 l/min. 500 ml of pre-culture 
were used to inoculate 9.5 l of the respective medium (see Table 4) for fermentation. There-
fore, five 500 ml Erlenmeyer flask, equipped with baffle, spiral and a silicon air vent cap (Sili-
cosen®) were each filled with 100 ml NL410 medium (see Table 3) and inoculated with 50 µL 
of the respective solution of cryopreserved spores. In case of foam development during the 
fermentation, the antifoam agent Ucolub N115® was added (see Table 4). 
Table 4. Parameters for batch fermentation of S. sp. Tü2700 & S. sp. Tü2401 
Strain Medium pH 
Incubation 
period [d] 
Amount of Ucolub 
N115® [ml] 
S. sp. Tü2700 NL19 7.5 7 4 
S. sp. Tü2401 OM 7.3 5 2 
2.3 Bioassays 
2.3.1 Agar diffusion assays 
Agar diffusion assays against E. coli K12 and B. subtilis 168 were performed in round 
(Ø = 92mm) or square (120 x 120 mm) petri dishes. Petri dishes were filled with 20 ml (40 ml 
for square) LB-agar (see Table 3) at T ~ 36 °C containing 50 µl (100 µl for square) of a main 
culture of E. coli K12, or B. subtilis 168 (see 2.2.2). Round wells (Ø = 7 mm) were made and 
filled with 50 µl of sample. Subsequently, plates were first incubated for 1 h, at ambient tem-
perature, before incubating for 16 h at either 30 °C (B. subtilis 168) or 37 °C (E. coli K12). Unless 
otherwise stated, 1 µl Gentamicin sulfate [c = 50 mg/ml in water] was spotted on the surface 
of the agar as positive control. 
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2.3.2 Bioactivity assay against S. aureus PC322 
Bioactivity assays against S. aureus PC322 were performed in round (Ø = 92mm) or square 
(120 x 120 mm) petri dishes. 320 μl 5-bromo-4-chloro-3-indoxyl-β-D-galactopyranoside 
(X- Gal) [20 mg/ml in DMSO], and 4 μl erythromycin solution [50 mg/ml in ethanol] were mixed 
with 40 ml TSA and supplemented with 2 ml of the main culture of PC322 (OD of 0.1).147 Sub-
sequently, the mixture was filled into petri dishes. After solidification, round wells (Ø = 7 mm) 
were made and filled with 50 µl of sample. Unless otherwise stated, 50 µl hamamelitannin 
solution [c = 2 mg/ml in DMSO] were used as positive control.140 
2.3.3  yorB Reporter gene assay 
The yorB reporter gene assays were kindly performed by Katharina Wex (Working group of 
Prof. Dr. Heike Brötz-Oesterhelt) at the IMIT. 
The yorB reporter gene assays were performed with Bacillus subtilis 1S34 pHJS105-yorB-lacZ2 
as agar diffusion assays.159 The assay was performed in square petri dishes (120 x 120 mm). 
20 ml LB medium supplemented with 1 mg spectinomycin were inoculated with 500 µl of an 
overnight culture and grown until reaching the stationary phase. This solution was used to 
inoculate 50 ml LB soft agar (0.7% agarose) containing 7.5 mg X-Gal up to the defined concen-
tration of 3 x 107 CFU/ml. Subsequently, the mixture was filled into petri dishes. After solidifi-
cation, round wells (Ø = 7 mm) were made and filled with 50 µl of sample. 5 µg ciprofloxacin 
were used as positive control.  
2.3.4 Bioautography 
Bioautography was performed subsequently to the TLC analysis of the bioactive fractions of 
the reverse extract of S. sp. Tü2401 submerse cultures derived from GFC (see 2.6.1). For this 
purpose, after drying, the TLC plates were transferred (face up) into square petri dishes 
(120 x 120 mm). Petri dishes were filled with 40 ml LB- agar (see Table 3) at T ~ 36 °C contain-
ing 100 µl of a main culture of E. coli K12 (see 2.2.2). Subsequently, plates were first incubated 
for 1 h at ambient temperature, before incubating for 16 h at 37 °C (E. coli K12). Unless other-
wise stated, 1 µl Gentamicin sulfate [c = 50 mg/ml in water] was spotted on the surface of the 
agar as positive control. 
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2.4 Sample preparation and extraction 
Extracts and reverse extracts from Streptomyces submerse cultures were generally obtained 
after 4 to 7 days of incubation. 
2.4.1 Preparation of cell free supernatant (CFS) samples 
1.0 ml of Streptomyces submerse culture was transferred into a 2.0 ml tube and subsequently 
centrifuged for 5 min at 13,000 rpm. Finally, the supernatant was filtered through a 
0.2 µm sterile filter. 0.5 ml of this CFS were transferred into an HPLC vial.  
2.4.2 Preparation of CFS extract samples 
CFS extract samples were prepared by adjusting the pH of CFS (see 2.4.1) to 5.0. The CFS was 
extracted with an equal amount of EA in an overhead shaker for 30 min. Subsequently, the 
organic phase was dried under reduced pressure. The pellet was dissolved in 0.5 ml methanol 
and centrifuged for 5 min and 13000 rpm. The supernatant was transferred into an HPLC vial. 
2.4.3 Preparation of biomass extracts 
The biomass was obtained by centrifuging 5 ml Streptomyces submerse culture for 5 min at 
13,000 rpm. The Pellet was extracted with 10 ml of a mixture of methanol and acetone  
(1:1; (v/v)) in an overhead shaker for 30 min. Afterwards, the organic phase was dried using a 
rotary evaporator. The pellet was dissolved in 1 ml methanol and centrifuged for 5 min at 
13000 rpm. The supernatant was transferred into an HPLC vial. 
2.4.4 Processing of fermentation broth 
After termination of the fermentation (see 2.2.4), 2% Celite® Hyflo Super-cel was added and 
the entire culture was separated by multiple sheet filtration (Pall T 1500 filter plates; relative 
retention range 10 - 30 µm) into culture filtrate (CFS) and mycelium.  
2.4.4.1 Extraction of the fermentation broth of S. sp. Tü2700 
The pH of the CFS was adjusted to pH 5 with 1 M HCl and extracted five times for 30 min with 
each 2.0 l of EA. The organic phases were combined and concentrated under reduced pressure. 
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2.4.4.2 Extraction of the fermentation broth of S. sp. Tü2401 
CFS was extracted five times for 30 min with each 2.0 l of EA. The organic phases were com-
bined and concentrated under reduced pressure. The aqueous phase was lyophilized (see 2.5). 
The residue of the extracted aqueous phase will be called “reverse extract” in the description 
of further processing steps below. 
2.4.5 Agar extraction of S. sp. Tü2401 
For the extraction from agar, S. sp. Tü2401 was cultivated on ISP2 agar plates. 2 plates 
(approx. 40 ml) were sliced, transferred into a 50 ml tube, and subsequently centrifuged at  
20 000 g for 30 min, resulting in 10 ml supernatant. After filtration trough a folded filter, the 
pH was adjusted to pH 4.0 using 0.1 M HCl. After centrifugation, (NH4)2SO4 was added to the 
supernatant up to the saturation point and incubated for 4 h at 4 °C. Afterwards, the precipi-
tate was separated and dissolved in 10 ml 0.1 M K2HPO4 at a pH of 8.0. Finally, this solution 
was extracted with 10 ml EA.160 After drying under reduced pressure, the pellet was dissolved 
in 2.0 ml MeOH. 
2.4.6 Determination of extraction conditions for S. sp Tü2401 submers cultures 
These experiments have been performed by Philipp Schneider during his master thesis under 
my supervision.161 
In order to determine the extraction conditions for S. sp Tü2401 submerse cultures, twenty 
15 ml tubes were filled with 5 ml CFS from S. sp Tü2401 submerse cultures. The pH was ad-
justed four times to either 2, 5, 7, 9, or 11 with 0.1 M NaOH or 0.1 M HCl. Subsequently, the 
samples were extracted with EA, methyl acetate, ethyl formate, or butanol. Finally, each phase 
was tested against E. coli K12 (see 2.3.1). 
2.4.7 Determination of extraction conditions for S. sp Tü2401 reverse extract 
In order to determine the extraction conditions for the reverse extract of S. sp Tü2401, eight 
1.5 ml tubes were filled with each app. 10 mg reverse extract from S. sp Tü2401 submerse 
cultures (2.4.4.2). Subsequently, the extract was dissolved in each 1 ml of a mixtures of MeOH 
and H2O (0 %; 30 %; 50 %; 80 % MeOH) each at pH of 2 and 7. After shaking for 30 min in the 
ultrasonic bath, the tube was centrifuged at 13,000 rpm. The supernatants were removed and 
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subsequently analysed using E. coli K12 agar diffusion assays (see 2.3.1). The pellets were once 
more dissolved in 1 ml of the respective mixture and extracted by shaking for 30 min in the 
ultrasonic bath. After centrifugation at 13,000 rpm, the supernatants were analysed using 
E. coli K12 agar diffusion assays. Meanwhile, the pellets were dried for 10 min at 60 °C and 
subsequently weighted. 
2.5 Lyophilisation 
Aqueous solutions, e.g. CFS of S. sp Tü2401, were frozen at – 80 °C and were subsequently 
dried using the Lyovac GT2 (Heraeus Holding, Hanau; Germany) according to the manufactur-
ers protocol. 
2.6 Bioactivity- guided isolation  
2.6.1 Thin-layer chromatography 
Bioactive fractions derived from GFC of the reverse extract of S. sp. Tü2401 submerse cultures 
were analysed using Thin-layer chromatography (TLC). Two different polar stationary phases 
were used (Silica gel 60 F254, and Silica gel 60 Diol F254 (Merck KGaA, Darmstadt, Germany)) 
with various mobile phase mixtures (see Table 28). Samples were applied stepwise, by spot-
ting 2 µl at a time approximately 1.5 cm from the bottom edge of the plate. After evaporation 
of the solvent, this procedure was repeated until 25 µl of each sample were applied. In the 
meantime, the TLC chambers were filled with a sufficient amount of the mobile phase to a 
depth of less than 1 cm. Additionally, filter paper soaked with the same mobile phase was 
attached to the walls of the chambers. The separation chambers were closed and stored for 
30 min at ambient temperature to saturate the air in the chambers with the mobile phase. 
Subsequently, the plates were placed in the chambers without allowing the sample spots to 
drown in the mobile phase. When the solvent front reached approx. 90 % of the plates maxi-
mum size, the TLC plates were removed from the chambers. After drying, the plates were 
initially analysed using UV light at λ = 366 nm (for fluorescent analytes) and at λ = 254 nm (for 
fluorescence quenching compounds). Finally, in order to visualize the compounds on the TLC 
plates, different reagents were sprayed onto the plates (orcinol, bromocresol green, or ninhy-
drin (see 2.6.1.1)), or the plates were submitted to bioautography analyses (see 2.3.4). 
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2.6.1.1 Staining agents 
2.6.1.1.1 Orcinol  
The orcinol staining solution was always prepared freshly by mixing the storage solutions A 
and B (ratio 10:1 (V/V). Solution A is 10 % sulfuric acid containing 1 % (w/V) Fe(III)Cl3. Solu-
tion B is an ethanolic solution of 6 % (w/V) orcinol. After staining, the TLC plates were stored 
for 1 min at 60 °C.  
2.6.1.1.2 Bromocresol green  
The bromocresol green staining solution was prepared by adding 0.04 g of bromocresol green 
to 100 ml ethanol. Subsequently, 0.1 M NaOH was added until the colour of the solution 
turned blue.   
2.6.1.1.3 Ninhydrin  
The ninhydrin staining solution was always prepared freshly by dissolving 0.1 g ninhydrin in a 
mixture of 100 ml acetone and 0.5 ml acetic acid. After staining, the TLC plates were developed 
for 5 min at 60 °C.  
2.6.2 Size-exclusion chromatography  
Gravity flow size-exclusion chromatography columns were prepared by soaking a sufficient 
amount of stationary phase material in the appropriate mobile phase for 4 h (see Table 5) to 
form slurry. Subsequently, this slurry was thoroughly transferred into the gravity flow glass 
column. The columns were flushed with the mobile phase for 4 - 5 h at a flow rate of 40 ml/h 
(Ø 2.5 ml) or 90 ml/h (Ø 5 ml). 
Samples were dissolved in 1 ml of the mobile phase (2 ml when loading mass exceeded 
200 mg) for 30 min under shaking in an ultrasonic bath. After centrifugation, the supernatant 
was loaded onto the columns.  
500 µl of each fraction were analysed via agar diffusion assays against S. aureus PC322 
(S. sp. Tü2700) or E. coli K12 (S. sp. Tü2401) (see 2.3). The active fractions were combined and 
analysed via HPLC. 
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Table 5. Characteristics of the SEC columns 
Material 
Exclusion 
Limits [Da] 
Column di-
mensions [cm] 
Mobile 
phase 
Flow rate 
[ml/h] 
Loading 
mass [mg] 
Fractionation 
interval [1/h] 
Sephadex™ LH20 ≤ 5000 2.5 x 90 H2O 34 104 3 
Sephadex™ LH20 ≤ 5000 2.5 x 78 MeOH 24 200 2 
Sephadex™ LH20 ≤ 5000 5.0 x 95 MeOH 102 1000 4 
Sephadex™ G15 ≤ 1500 2.5 x 90 H2O 36 105 3 
Bio-Gel® P2 100 - 1800 2.5 x 90 H2O 45 103 3 
Toyopearl® HW40 100 - 10000 2.5 x 90 H2O 36 105 3 
2.6.3 MPLC 
MPLC was performed on a preparative HPLC consisting of an injection valve (Valco C6UW with 
5 ml Sample loop; Macherey & Nagel, Düren), Chromatograph LaPrep with two P119 pumps 
(VWR, Darmstadt), dynamic mixing chamber (Knauer, Berlin), P314 2-chanal-UV-Vis detector 
(VWR) with 2-channel- recorder (Modell N-2, Abimed, Langenfeld). A 12 g Sepacore Silica HP 
column (Büchi Labortechnik AG, Flawil, Switzerland) with a CV of 17 ml was used for the sep-
arations. 
Samples were applied via dry loading. Therefore, 40 mg of the bioactive fractions were dis-
solved in 80 % MeOH/H2O (V/V) in a round flask. Approximately 1 g silica gel was added and 
thoroughly mixed with the dissolved fractions. Subsequently, the solvent was removed under 
reduced pressure. As a result, the bioactive fractions from the GFC adhered to the silica gel. 
This silica gel was transferred into an empty column and compacted by tamping. Emerging 
void volume was filled with sea sand until the column was tightly packed.  
Prior to the separation the 12 g Sepacore Silica HP column was activated and conditioned for 
5 min at a flow rate of 18 ml/min with 100 % MeOH. The flow was stopped and the column 
containing the sample was connected to the system. For detection, the wavelength 210 nm 
and 280 nm have been used. The separation was started by executing a gradient from  
100 % MeOH to 50 % MeOH/H2O [pH2] in 15 min at a flow rate of 18 ml/min. Samples were 
taken every minute and 50 µl were analysed using E. coli K12 agar diffusion assays (see 2.3.1). 
The bioactive fractions were combined and analysed via HPLC.  
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2.6.4 Analytical HPLC and MS 
The components for HPLC and HPLC-MS analysis using either an Agilent Technologies 1260 
Infinity (HPLC), or an Agilent Technologies 1000 (HPLC-MS) (Agilent, Waldbronn) are specified 
in Table 2. For analytical measurements, a standard 10 mm flow cell was used, whereas for 
semi-preparative analysis a 3 mm flow cell was installed. The following tables contain param-
eters used for different separations. Prior to the analysis, samples were centrifuged at 
13000 rpm and supernatants were transferred into HPLC vials. The HPLC data were analysed 
using the Agilent Chemstation (Version B.04.03). The HPLC-MS data were analysed with Bruker 
DataAnalysis for 6300 Series IonTrap LC-MS (Version 3.4). 
Table 6. Parameter of the HPLC screening method using the Luna® C18 column. 
Parameter Value 
Machine Agilent Technologies 1260 Infinity   
Column Luna® C-18; 5 µm; 100  Å; 4.6 mm x 250 mm  
Column oven 30 °C  
Solvents A: H2O + 0.1 % FA; B: ACN + 0.1 % FA   
Method Gradient 5 - 100 % B for 20 min; Plateau 100 % B for 5 min 
Flow 2.5 ml/min   
Detektor UV/ DAD: 210-500 nm; ELSD   
Injection volume 5 µl (analytical); 50 µl (semi-preparative)   
[Fraction collector: time based with timeslices 2/min]      
Table 7. Parameter of the HPLC screening method using the Nucleosil 100 C18 column. 
Parameter Value 
Machine Agilent Technologies 1260 Infinity   
Column Nucleosil 100 C-18; 5 µm; 100  Å; 4.6 mm x 125 mm  
Column oven 30 °C  
Solvents A: H2O + 0.1 % FA; B: ACN + 0.1 % FA   
Method Gradient 0 - 100 % B for 15 min; Plateau 100 % B for 3 min 
Flow 2.0 ml/min   
Detektor UV/ DAD: 210-500 nm; ELSD   
Injection volume 5 µl (analytical); 50 µl (semi-preparative)   
[Fraction collector: time based with timeslices 2/min]      
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Table 8. Parameter of the HPLC-MS screening method using the Nucleosil 100 C18 column. 
Parameter Value 
Machine Agilent Technologies 1200    
Column Nucleosil 100 C-18; 5 µm; 100  Å; 3.0 mm x 150 mm  
Column oven 30 °C  
Solvents A: H2O + 0.1 % FA; B: ACN + 0.06 % FA   
Method Gradient 0 - 100 % B for 15 min; Plateau 100 % B for 2 min 
Flow 0.4 ml/min   
Detektor UV/ DAD: 210-500 nm   
Injection volume 2.5 µl      
Machine Mass spectrometer 6330 Iontrap LC/MS   
Ionisation Electrospray ionisation (pos. & neg. mode alternating) 
Capillary Voltage  3.5 kV   
Injector Temperature  350 °C   
Target mass  400 m/z; 800 m/z; 1000 m/z     
Table 9. Parameter of the HPLC method using the Nucleosil 100 C8 column. 
Parameter Value 
Machine Agilent Technologies 1260 Infinity   
Column Nucleosil 100 C-8; 5 µm; 100  Å; 4.6 mm x 125 mm  
Column oven 30 °C  
Solvents A: H2O + 0.1 % FA; B: ACN + 0.1 % FA   
Method Gradient 0 - 100 % B for 15 min; Plateau 100 % B for 3 min 
Flow 2.0 ml/min   
Detektor UV/ DAD: 210-500 nm; ELSD   
Injection volume 50 µl    
Fraction collector  time based with timeslices 2/min     
Table 10. Parameter of the HPLC method using the Kinetex® Polar C18 column. 
Parameter Value 
Machine Agilent Technologies 1260 Infinity   
Column Kinetex® Polar C-18; 2.6 µm; 100  Å; 4.6 mm x 150 mm 
Column oven 50 °C 
Solvents A: H2O + 0.1 % FA; B: ACN + 0.1 % FA   
Method Gradient 5 - 100 % B for 20 min; Plateau 100 % B for 5 min 
Flow 1.2 ml/min   
Detektor UV/ DAD: 210-500 nm; ELSD   
Injection volume 25 µl    
Fraction collector  time based with timeslices 2/min     
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Table 11. Parameter of the HPLC method using the Luna® NH2 column. 
Parameter Value  
Machine Agilent Technologies 1260 Infinity  
Column Luna® NH2; 5 µm; 100  Å; 4.6 mm x 250 mm 
Column oven 30 °C 
Solvents A: H2O + 0.1 % FA; B: ACN + 0.1 % FA  
Method 80 % B for 20 min  
Flow 2.0 ml/min  
Detektor UV/ DAD: 210-500 nm; ELSD  
Injection volume 50 µl   
Fraction collector  time based with timeslices 2/min   
Table 12. Parameter of the HPLC method using the SeQuant® ZIC®-HILIC column. 
Parameter Value 
Machine Agilent Technologies 1260 Infinity   
Column SeQuant® ZIC®-HILIC; 3.5 µm; 100  Å; 4.6 mm x 150 mm 
Column oven 30 °C 
Solvents A: 10 mM NH4CH3COO; B: ACN + 0.1 % FA  
Method 80 % B for 20 min   
Flow 2.0 ml/min   
Detektor UV/ DAD: 210-500 nm; ELSD   
Injection volume 50 µl    
Fraction collector  time based with timeslices 2/min     
Table 13. Parameter of the HPLC method for the isolation of albomycins using the XBridge 
BEH Amide column. 
Parameter Value 
Machine Agilent Technologies 1260 Infinity   
Column XBridge BEH Amide; 5 µm; 130  Å; 4.6 mm x 250 mm   
Column oven 30 °C  
Solvents A: ACN/H2O/100mM NH4COO pH3 (5:4:1);B: ACN/100mM NH4COO pH3 (9:1)   
Method Plateau 80 % B for 5 min; Gradient 80 - 60 % B for 35 min; Plateau 60 % B for 
5 min 
Flow 1.0 ml/min   
Detektor UV/ DAD: 210-500 nm; ELSD   
Injection volume 50 µl    
Fraction collector  time based with timeslices 2/min     
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Table 14. Parameter of the HPLC method determining the most suitable pH for the separa-
tion of albomycins using the XBridge BEH Amide column. 
Parameter Value     
Machine Agilent Technologies 1260 Infinity   
Column XBridge BEH Amide; 5 µm; 130  Å; 4.6 mm x 250 mm   
Column oven 30 °C  
Solvents A: 10 mM NH4CH3COO (pH 3; 6; 8.5); B: ACN   
Method Plateau 95 % B for 5 min; Gradient 95 - 60 % B for 20 min; Plateau 60 % B 
for 5 min 
Flow 1.0 ml/min   
Detektor UV/ DAD: 210-500 nm; ELSD   
Injection volume 50 µl    
Fraction collector  time based with timeslices 2/min     
Table 15. Parameter of the HPLC method determining the best gradient for the separation of 
albomycins using the XBridge BEH Amide column. 
Parameter Value     
Machine Agilent Technologies 1260 Infinity   
Column XBridge BEH Amide; 5 µm; 130  Å; 4.6 mm x 250 mm   
Column oven 30 °C  
Solvents A: ACN/H2O/100mM NH4COO pH3 (5:4:1);B: ACN/100mM NH4COO pH3 
(9:1)   
Method Plateau 95 (70) % B for 5 min; Gradient 95 (70) - 60 % B for 20 min; Plat-
eau 60 % B for 5 min 
Flow 1.0 ml/min   
Detektor UV/ DAD: 210-500 nm; ELSD   
Injection volume 50 µl    
Fraction collector  time based with timeslices 2/min     
2.6.5 HPLC-HR-MS analysis 
For HPLC-HR-MS analysis, ESI (positive and negative ionization) was performed in Ultra Scan 
mode with a capillary voltage of 3.5 kV and drying gas temperature of 350 °C. To obtain 
HR-MS data, samples were applied to a Dionex Ultimate 3000 HPLC system (Thermo Fisher 
Scientific), coupled to a maXis 4G ESI-QTOF mass spectrometer (Bruker Daltonics). The follow-
ing solvent composition was used to separate the analytes 0.1 % formic acid in water as sol-
vent A and 0.06 % formic acid in MeOH as solvent B, with a gradient from 10 % to 100 % B over 
20 min, followed by 100 % B for 5 min at a flow rate of 0.3 ml/min. The separation was carried 
out on a Nucleoshell C18 column, 2.7 μm, 150×2 mm (Macherey-Nagel). The ESI source was 
operated at a nebulizer pressure of 2.0 bar, and drying gas was set to 8.0 l/min at 350 °C. 
MS/MS spectra were recorded in auto MS/MS mode with collision energy stepping enabled. 
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The scan rates for full scan and MS/MS spectra were set to 1 Hz and 7 Hz, respectively. Sodium 
formate was used as internal calibrant in each analysis. Molecular formulae were calculated 
from monoisotopic masses using the SmartFormula function of DataAnalysis (Bruker Dalton-
ics). 
2.6.6 Preparative HPLC 
Preparative HPLC was performed on a preparative HPLC consisting of an injection valve (Valco 
C6UW with 5 ml Sample loop; Macherey-Nagel, Düren), Chromatograph LaPrep with two  
P119 pumps (VWR, Darmstadt), dynamic mixing chamber (Knauer, Berlin), P314 2-chanal-UV-
Vis detector (VWR) with 2-chanal- recorder (Modell N-2, Abimed, Langenfeld). The separation 
parameters for the isolation of oxazolomycin are described in Table 16. Prior to the analysis, 
samples were centrifuged at 13000 rpm and supernatants were injected into the HPLC. Frac-
tions were collected peak based by hand, and analysed subsequently via HPLC (see Table 6). 
Table 16. Parameter of the HPLC method for the isolation of oxazolomycin A using a  
Luna® C-18 column 
Parameter Value 
Machine Chromatograph LaPrep    
Column Luna® C-18; 5 µm; 100  Å; 10 mm x 250 mm  
Column oven 30 °C  
Solvents A: H2O; B: ACN   
Method Isocratic 40 % B for 10 min; Gradient to 100 % B in 1 min; Plateau 100 % B for 
5 min 
Flow 9.45 ml/min   
Detektor UV: 230 nm; 280 nm   
Injection volume 300 µl      
Fractionation: peak based by hand      
2.7 Stability analysis of oxazolomycin A 
In order to examine the stability of oxazolomycin A, stress tests have been performed. 5 mg of 
the pure compound were dissolved in 5 ml MeOH [c = 1 mg/ml]. After centrifugation, the su-
pernatant was dispensed equally in 25 HPLC vials. 3 vials were stored under each of the con-
ditions listed in Table 17. In order to create an inert atmosphere above the sample solution, 
the void volume of the HPLC vials was flushed with argon gas for 30 s. Light protection was 
created by wrapping the HPLC vials in aluminium foil and storing them in a light protective box. 
Samples were either stored in the fridge at 4 °C, in the hot cabinet at 60 °C, or at ambient 
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temperature (about 23 °C). The samples were analysed at the start of the experiment, after 
17 h and after 77 h via HPLC (see Table 7). The maximum peak heights at 280 nm were com-
pared. The degradation [%] was calculated according to formula (1).  
(1) Degradation [%] =
hT0
280 nm−hTx
280 nm
hT0
280 nm ∗ 100 
 
Table 17. Storage conditions of stability tests of oxazolomycin A 
Atmosphere Light protection Temperature [°C] 
Air - 23 
Air + 23 
Argon + 23 
Argon + 4 
Argon + 60 
Argon + 23 
Argon - 23 
2.8 NMR analysis 
The NMR experiments were performed on a Bruker Avance III HD 400 spectrometer at 
400 MHz (1H). The compounds were dissolved in methanol-d4. This solution was filtered 
through cotton wool and transferred into an NMR tube (filling height: 4 cm). The chemical 
shifts were referenced to the residual protonated solvent signals of methanol-d4  
(δH = 3.31 ppm & δH = 4.78 ppm; δC = 49.15 ppm).  
2.9 DNA Isolation 
To obtain genomic DNA for sequencing, main cultures of the Streptomyces strains were used 
after 4 d of incubation. To isolate the genomic DNA, the Qiagen Genomic-tip 100/G kit  
(Qiagen,Hilden, Germany) was used, following the manufacturer’s protocol. 50 µl deionised 
H20 were used for elution. 
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3. Results & Discussion 
3.1 Screening of the Tübingen strain collection of Actinobacteria 
3.1.1 Development of a cultivation system 
Small-scale cultivation systems using microtiter plates (MTP) are widely used in microbiology 
labs throughout the world.162–166 There are even reports of applications of low volume cultiva-
tion systems for filamentous organisms like streptomycetes.166–171 In recent years, cultivation 
in an even smaller scale than MTP, in picodroplets, has made great progress.172–176 The ad-
vantages of these high-throughput (HTP) cultivation systems are apparently the increased 
time- and space- efficiency while handling and screening large amounts of different bacteria 
strains.176 Moreover, the development of picoinjection systems, enabling the injection of re-
porter cells into the droplets, allowed screening for antimicrobial compounds in pi-
codroplets.174 However, no new antimicrobial compound has been identified through this new 
approach yet.174  
As mentioned in the introduction (see 1.2), Actinobacteria are soil bacteria which undergo a 
complex life cycle from spore germination over vegetative growth, formation of aerial hyphae, 
spore formation, and finally spore dispersal.28 However, all cultivation systems reported to 
date are submerse cultivation systems. Needless to say that these systems led to the identifi-
cation of a plethora of natural products from Actinobacteria. Nevertheless, cultivation in sub-
merse cultures is still an artificial way of growing, and relatively little is known yet about the 
morphogenesis of Actinobacteria in submerse cultures.177,178 Antibiotic production is influ-
enced by the morphology in submerged cultures, which can range from fragmented growth to 
dense clumps.28 For example, production of erythromycin in Saccharopolyspora erythraea is 
promoted by clumps of at least 90 μm in diameter. All morphologies differing from these 
clumps leads to diminished yields.179  
Keeping in mind the tremendous influence of the cultivation conditions on the production of 
secondary metabolites, this work aimed at the development of an agar based MTP (96 well) 
cultivation system for Actinobacteria.28,30 Additionally, this cultivation system needed to be 
connectable to a suitable screening system. 
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In parallel to the development of the cultivation system, the Tübingen strain collection, which 
currently comprises more than 1000 Actinobacteria strains, was formatted in a 96 well MTP 
format. Therefore, spores of each strain were harvested according to 2.2.3.2. But instead of 
filling the spore solutions into cryotubes, they were transferred into MTPs (96-deepwell, flat 
bottom, square). These MTPs were stored at -80 °C.  
Antibiotic production is growth phase dependent, mostly appearing during vegetative 
growth.28 Hence, in order to harvest all strains after incubation during their vegetative growth 
phase, it was necessary to sort strains, whose sporulation occurred around the same time, into 
the same MTP. 
After incubation, the agar blocks, containing the Actinobacteria strains needed to be trans-
ferred into petri dishes to subsequently perform bioassays. While using standard MTP, it was 
impossible to non-destructively remove the agar blocks from the MTP. Removal of the bottoms 
of the wells was the solution to this problem. Thereby, the agar blocks could be pushed out of 
the MTP. However, neither could the bottoms been removed sterile nor was it possible to de-
velop a supplementary sterilization method, nor could bottomless MTP been purchased. 
Standard MTP consists of polystyrene which is not heat stable. Hence treatments like (moist) 
heat sterilization were not applicable. But also chemical sterilization according to the Centers 
of Disease Control and Prevention (CDC) Guidelines, employing 7.5 % H2O2 for 15 min and 
70 % ethanol for 5 min failed in their effectiveness.180 
Due to these sterility problems, the Actinobacteria strains were finally cultivated in bottom-
less, stainless-steel MTPs (96-well, round). These plates are reusable and could be heat steri-
lized at 160 °C for 2 h. 
Before being used for the cultivation of Actinobacteria, the plates were closed on one site with 
a silicone mat. Each well was filled with 160 µl of either ISP-2 or ISP-3 agar (see Figure 2A). For 
further processing, it was necessary to increase the amount of agar in the media from 2.0 % 
to 2.5 %.  
A cryo-replicator, developed by Duetz et al., was used for inoculation of these MTPs from the 
frozen spore stocks.168 This replicator was designed to remove small aliquots from the frozen 
stocks, without allowing the whole stock to thaw, since this would lead to a rapid loss of spore 
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viability (see Figure 2B).168 The replicator consists of 96 spring-borne stainless steel pins. For 
inoculation, the cryo-replicator is pressed (app. 0.2 N) for 3 s onto the frozen surface of the 
spore stock.168 This leads to the melting of app. 0.3 µl of the spore stock, which will form an 
app. 50 µm film on the tip of the pin.168 Subsequently, this spore film was used for inoculation 
of the agar-filled MTPs (see Figure 2C). Finally, the MTPs were closed with another silicone 
matt and incubated at 27 °C for 5 to 10 d, depending on the sporulation times ( see Figure 2D). 
In order to prevent the agar from drying during incubation, the MTP were stored in a water 
saturated atmosphere in desiccators.  
Between inoculations, the cryo-replicator was heat sterilized and allowed to cool down to am-
bient temperature.168 
In order to analyse the possibility of cross contamination, MTPs were prepared, containing an 
Actinobacteria spore stock only in every third well. This plate was used for iterative inocula-
tions of agar filled MTPs. Throughout this analysis contamination of adjoining wells has never 
been observed. 
3.1.2 Development of the screening system 
Agar diffusion assays are basic tools in microbiology. The susceptibility of bacteria towards 
certain compounds is analysed by spotting the compounds on an agar plate, where bacteria 
have already been placed. The occurrence of an inhibition zone around the compounds, also 
called halo, indicates if growth of the bacteria was affected.181 The size of the halo does not 
only depend on the susceptibility of a bacterium towards the compound, but also on the com-
pounds diffusion coefficient.182 The discovery of penicillin has been one of the very first re-
ported agar diffusion assays.22 Meanwhile, agar diffusion assays can be used for various appli-
cations either to detect the susceptibility of an organism towards a certain compound, to 
quantify compounds, or to identify mode of actions.183–185 Even combinations of agar diffusion 
test with analytical techniques like TLC or MS have been reported.186,187 
However, there are no assays described in the literature that combine agar diffusion assays 
with MTP cultivation systems. In order to screen the Tübingen strain collection for the produc-
tion of QS inhibitory metabolites, it was necessary to develop a screening system suitable for 
the combination of the above mentioned MTP cultivation system with an agar diffusion assay. 
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Figure 2. "From spore to bioactivity" - the workflow of the combined MTP cultivation sys-
tem and an agar diffusion assay. (A) Bottomless, stainless steel MTP were closed with silicone 
mats and wells were filled with agar. (B) For spore sampling, the cryo-replicator is pressed onto the 
frozen surface of the spore stock, leading to a 50 µm film on the tip of the pin. (C) The agar filled MTP 
were inoculated, sealed with another silicone mat and stored in a water filled desiccator (D). (E) After 
an appropriate time of incubation, the MTP were unsealed and the growth of the bacteria was ana-
lysed. (F) With the help of two plungers, agar plugs containing the bacteria were redistributed in two 
petri dishes. (G) Those plugs were subsequently submitted to bioassays. 
To withdraw the agar plugs from the MTPs after the appropriate incubation time, plungers 
have been developed to push the agar plugs out of the bottomless MTPs (see Figure 2E&F). 
These plungers have been designed to be heat sterilisable, thus consisting of aluminium han-
dles with Teflon pins. Instead of a flat shape the tips of the pins are concaved. This has been 
found to be necessary to reduce the contact area of the pins and the agar plugs, thus prevent-
ing adhesion of the plugs to the pins 
 In order to create sufficient distance between the agar plugs in the petri dish, it was necessary 
to distribute the 96 agar plugs of one MTP into two petri dishes (square; 100 x 100 mm). 
Hence, two plungers each consisting of 48 pins alternating pin and gap, were build. 
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After transferring the agar plugs into the petri dishes, 40 ml agar, supplemented with the test 
organism, were carefully poured around the agar plugs (see Figure 2G). The agar plates were 
kept at ambient temperature for 1 h and subsequently incubated over night at either 27 °C or 
36 °C, depending on the test organism. 
3.1.3 Bioactivity screening against S. aureus PC322  
1232 strains from the Tübingen strain collection of Actinobacteria have been tested against 
S. aureus PC322, using the combined cultivation / screening system described above (see 3.1.1 
& 3.1.2.).147 As already mentioned, the cultivation conditions have a tremendous impact on 
the secondary metabolite profile of Actinobacteria, therefore the strains were cultivated on 
two different media: ISP2 and ISP3 (see Table 3).30 These two media have been developed in 
the course of the International Streptomyces Project, representing two recommended media 
for the cultivation of Actinobacteria.188,189  
 
Figure 3. Probable outcomes of the S. aureus PC 322 agar diffusion assay (see 2.3.2). A, B, C 
represent different Actinobacteria that were grown on agar and have been subsequently placed in a 
petri dish. Agar supplemented with S.aureus PC322, X-Gal and Erythromycin was poured around the 
plugs. After incubation, 3 different outcomes could be observed. (A) No inhibition, neither of growth 
nor of QS; (B) quorum sensing inhibition, indicated by hazy, uncolored inhibition zones; (C) growth 
inhibition, indicated by clear inhibition zones 
The combined cultivation/screening experiments were performed in triplicates, in order to re-
duce the effect of random errors, e.g. growth deficiencies, on the screening results. Only those 
effects occurring at least two times were taken into account as reliable results. 
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Three different outcomes could be observed during the screening: A) no bioactivity, B) quorum 
sensing inhibition activity, and C) antibacterial activity (see Figure 3). 
  
Figure 4. Results from the screening of 1232 Actinobacteria strains from the Tübingen strain 
collection against S. aureus PC322. 82 strains showed quorum sensing inhibition activity (QSI), while 
284 strains exhibited antibacterial activity (AB). 866 strains did not reveal any activity (NA). 
Independently from the cultivation medium, 82 strains showed quorum sensing inhibition ac-
tivity, representing approx. 7 % of the tested strains (see Figure 4). While the majority of those 
strains (80 %) only exhibited modest inhibition zones smaller than 0.5 cm, 17 strains showed 
inhibition zones bigger than 1.0 cm (see Table 18). 5 strains (Tü99; Tü1792; Tü2698; Tü2700, 
and Tü3337) even showed halos of at least 2 cm. However, some data sets showed bad quality, 
e.g. impurities, short PCR fragments, and thus led to ambiguous resemblance. 
The impact of the cultivation conditions is also visible in this screening. Among the strains 
exhibiting inhibition zones ≥ 1 cm, 4 strains exclusively inhibited QS when cultivated on ISP3 
agar, while 9 strains revealed inhibition only when grown on ISP2 agar. 4 strains exhibited QS 
inhibition independently from the cultivation medium.   
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Table 18. Strains of the Tübingen strain collection of Actinobacteria exhibiting QS inhibition 
against the monitor strain S. aureus PC322 with inhibition zones ≥ 1 cm. The genus has been 
determined via 16S rRNABLAST analysis. Ambiguous results are indicated with N/A 
ISP-2 ISP-3 
Strain number Genus Strain number Genus 
Tü1471  N/A Tü35  Streptomyces 
Tü1792  Streptomyces Tü99  Streptomyces 
Tü2395 Streptomyces Tü1792  Streptomyces 
Tü2431  N/A Tü2644  Streptomyces 
Tü2469 Streptomyces Tü2698  Streptomyces 
Tü2698  Streptomyces Tü2700  Streptomyces 
Tü2700  Streptomyces Tü3004  N/A 
Tü3004  N/A Tü3676  Streptomyces 
Tü3054  Streptomyces   
Tü3084  Streptomyces   
Tü3337  Streptomyces   
Tü3374   N/A   
Tü6438  Streptomyces     
Overall, 284 strains showed antibacterial activity against S. aureus PC322, representing 23% of 
the screened strains (see Figure 4). 4 % of the strains even exhibited inhibition zones larger 
than 2.0 cm (see Table 19). Due to 16S-rRNA sequence identity, all of these strains belong to 
the genus Streptomyces. That was revealed by a BLAST search for resemblance of the  
16S-rRNA sequence of the strains in the NCBI database, identifying a collection of Streptomy-
ces with > 99 % sequences identity.190 4 strains exhibited their activity exclusively on ISP2 me-
dium, and 2 strains only on ISP3 medium, which is another confirmation of the OSMAC strat-
egy (see 1.2). The large amount of 23 % strains exhibiting antibacterial activities is not surpris-
ing, since especially the genus Streptomyces is well known for its potential to produce antibi-
otics (see 1.2), and the Tübingen strain collection contains preselected Actinobacteria strains. 
However, 866 strains did not show any activity against the monitor strain S. aureus PC322 
While among the strains exhibiting QS inhibitory activity, Streptomyces sp. Tü2700 was the one 
with the biggest zone of inhibition (2.5 cm), Streptomyces sp. Tü2401 was the most promising 
strain exhibiting anti-bacterial activity (2.2 cm). Thus these strains were chosen for further 
analysis, which will be presented in the following chapters.  
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Table 19. Strains of the Tübingen strain collection of Actinobacteria exhibiting antibacterial 
activity against the monitor strain S. aureus PC322 with inhibition zones ≥ 2 cm. The genus 
has been determined via 16S rRNA BLAST analysis. When strains have already been characterized for 
the specialized metabolites they produce, their antibacterial metabolites are also shown. 
ISP-2 ISP-3 
Strain number Genus Metabolites Strain number Genus Metabolites 
Tü735  Streptomyces Tetracyclin Tü39  Streptomyces 
Actinomycin, 
Chloractinomycin 
Tü2293 Streptomyces N/A Tü735 Streptomyces Tetracyclin 
Tü2401 Streptomyces N/A Tü2293 Streptomyces N/A 
Tü2687 Streptomyces N/A Tü2401 Streptomyces                  N/A 
Tü3775 Streptomyces N/A Tü2687 Streptomyces N/A 
Tü3938 Streptomyces N/A Tü3158  Streptomyces                  N/A 
Tü4116 Streptomyces N/A Tü3775 Streptomyces N/A 
F86 Streptomyces N/A     N/A 
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3.3 Streptomyces sp. Tü2700 
3.3.1 Taxonomy 
Strain Tü2700 is a member of the genus Streptomyces, as shown by its 16S rRNA sequence 
(> 99 % sequence identity with several Streptomycetaceae).190 However, this method is unable 
to reveal the distinct species of Streptomyces sp. Tü2700. Therefore, the genomic DNA was 
isolated, using the Qiagen Genomic-tip 100/G kit (Qiagen, Hilden, Germany) following the 
manufacturer’s protocol. Subsequently, the whole genome was sequenced. Finally, the se-
quence was submitted to the autoMLST program in order to automatically generate a species 
phylogeny with reference organisms, identifying the phylogenetic neighbours.191–193 As a re-
sult, the two type strains Streptomyces alboflavus NRRL B-2373 and Streptomyces aureocircu-
latus NRRL ISP5386 appeared as the closest relatives with an estimated average nucleotide 
identity (ANI) of 86.0 % (Mash distance: 0.1404) for Streptomyces alboflavus NRRL B-2373, re-
spectively 85.3 % (Mash distance: 0.1475) for Streptomyces aureocirculatus NRRL ISP5386. 
These results indicate that Streptomyces sp. Tü2700 apparently belongs to a yet undescribed 
species (Figure 5). However, in order to confirm this hypothesis further experiments determin-
ing its chemotaxonomy, eg. lipid profile, its morphology, and its utilization of different carbon 
sources are needed.  
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Figure 5. Phylogenetic tree of S. sp. Tü2700 (blue font) inferred from its gDNA sequence using the 
software autoMLST. The phylogeny is rooted with Actinospica acidiphila NRRL B24431 (red), strains 
depicted in green font represent Streptomyces type strains. 
58 3 Results & Discussion 
3.3.2 Primary screening 
The aim of this primary screening was the analysis of the biosynthetic potential of Streptomy-
ces sp. Tü2700, as well as the dereplication of the bioactive compound(s) with the help of an 
in-house spectral-database.   
3.3.2.1 Cultivation in different media 
Several sequencing projects have confirmed that Actinobacteria have a huge biosynthetic po-
tential.45–47 However, many of the biosynthetic gene clusters remain “silent”. In order to in-
crease the number of secondary metabolites available from one microbial source, Bode et al. 
have investigated the influence of the media composition.30 By altering the cultivation param-
eter, the so called OSMAC (One strain many compounds) approach resulted in more than 
100 compounds, belonging to various structural classes from 6 different organisms.30 
Therefore, following this OSMAC approach, Streptomyces sp. Tü2700 was cultivated in differ-
ent media. Subsequently, the potential to produce bioactive secondary metabolites was eval-
uated using bioactivity tests. Additionally, this primary screening aimed at the dereplication of 
bioactive compounds utilizing an in-house database.  
Streptomyces sp. Tü2700 was cultivated according to 2.2.3. After 72 h and 120 h, the pH and 
the amount of biomass were analysed (see Table 20). The pH value as well as the biomass 
show a constant increase over time in most media. Exceptions are NL200, NL400, NL410 and 
NL500, showing a constant or even decreasing biomass, and NL300, exhibiting a slight de-
crease of the pH value.194 A decline in biomass as well as of pH could be a sign of a bacterial 
colony being already in the death or decline phase of growth.195 A variety of reasons can be 
responsible. Either growth of Streptomyces sp. Tü2700 is accelerated in these media, which 
leads to populations being faster in the stationary growth phase. However, this seems unlikely, 
since media like e.g. NL19 show a similar increase in biomass (60 %) and no decline in pH. 
Thereby, the most possible explanation is that these media have to some extant a nutrient 
limitation, leading to smaller populations that reach the stationary growth phase faster. 
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Table 20. Results of the cultivation experiments of Streptomyces sp. Tü2700 in different me-
dia after 72 h & 168 h incubation. 
 Time [h] 
Biomass 
[%] 
pH CFS Colour Medium  Colour CFS 
Colour bio-
mass 
NL 19 
72 6 7,6 
beige 
light-grey beige 
168 10 8.2 light-brown light-brown 
NL 200 
72 2 6,7 
light-grey 
yellow dark-grey 
168 1 8.9 yellow light-grey 
NL 300 
72 7 7,5 
dark-brown 
light-brown light-brown 
168 12 7.3 red light-brown 
NL 333 
72 3 7,9 
light-brown 
yellow light-grey 
168 5 8.4 light-brown beige 
NL 400 
72 1 4,5 
yellow 
yellow beige 
168 1 4.8 yellow beige 
NL 410 
72 5 4,2 
light-brown 
yellow light-grey 
168 5 4.5 dark-brown light-grey 
NL 500 
72 1 3,9 
light-grey 
light-grey dark-grey 
168 1 4.2 beige dark-grey 
OM 
72 3 4,7 
beige 
beige beige 
168 4 4.8 red beige 
3.3.2.2 Biological screening 
In order to analyse the impact of the cultivation conditions on the bioactivity, extracts of the 
biomass as well as the CFS were prepared according to 2.4 and subsequently tested against 
S. aureus PC322, according to 2.3.2. The size and the appearance of halos were evaluated after 
12 h (see Table 21). In general, the extracts of the CFS or the biomass showed higher activity 
than the CFS itself, which is most probably a concentration effect. Additionally, extracts and 
CFS of cultures grown in media like NL200, NL400, NL410, NL500 and OM showed only slight 
activities. 
Depending on the media composition and the incubation time, extracts and CFS showed un-
stained halos varying in size and appearance, either clear or hazy, whereas hazy halos could be 
an indication for QSI in S. aureus PC322. 
Two media, NL19 and NL333, showed remarkable inhibition zones, with halo sizes above 
1.5 cm. However, this study aimed at the identification of novel QS inhibitors against S. aureus. 
Therefore, since extracts and CFS of cultures grown in NL19 have shown solely hazy halos, 
further cultivation studies were performed in NL19.194 Since the bioactivity of the CFS extracts 
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has increased after 72 h, it can be assumed that the optimal incubation time is longer than 
3 days.  
Table 21. Results of the bioactivity tests of CFS and extracts of Tü2700 against S. aureus 
PC322 after incubation times of 72 h and 168 h (- … no bioactivity; + … halo size ≤ 0.5 cm; ++ … halo 
size ≤ 1.5 cm; +++ … halo size > 1.5 cm; (c)… clear halo; (h)… hazy halo). 
  Time [h] CFS CFS extract Biomass extract 
NL 19 
72  -  ++ (h)  + (h) 
168  -  +++ (h)  + (h) 
NL 200 
72  -  -  + (h) 
168  -  -  + (c) 
NL 300 
72  -  ++ (h)  - 
168  + (c)  ++ (c)  + (c) 
NL 333 
72  + (h)  +++ (c)  ++ (c) 
168  + (c)  +++ (c)  ++ (c) 
NL 400 
72  -  -  + (c) 
168  -  + (h)  + (h) 
NL 410 
72  -  -  - 
168  -  -  - 
NL 500 
72  -  -  - 
168  + (h)  + (h)  + (h) 
OM 
72  -  -  - 
168  -  -  + (c) 
3.3.2.3 Microfractionation and dereplication of the bioactive Extract 
In a first attempt to dereplicate the potential QS inhibiting compound produced by Streptomy-
ces sp. Tü2700, the CFS extract of the culture grown in NL19 was microfractionated (see Table 
6). The fractions were dried, redissolved in MeOH, and subsequently tested against S. au-
reus PC322 according to 2.3.2. As a result, only fraction 11 showed a hazy halo. This fraction 
featured, along some smaller peaks, one very prominent peak. However, comparison of the 
UV spectra of the peaks with the in-house database did not reveal any accordance. Therefore, 
it was assumed that the compound responsible for the hazy halo is unknown. 
Needless to say, that this dereplication method has limitations, since the in-house database 
only covers 976 natural products (as at 01/2018). Additionally, signal overlapping of coeluting 
compounds is a known restraint of dereplication methods using crude extracts. Furthermore, 
compounds featuring no chromophore in the molecular structure cannot be dereplicated by 
the use of this method. However, all compounds known so far that interfere with S. aureus QS 
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feature chromophores.115,120 Nevertheless, it would have been useful to expand the dereplica-
tion efforts and include also external NP databases like the dictionary of natural products. 
Moreover, since the combination of UHPLC and HR-MS-MS has been shown to be a promising 
tool for the dereplication of natural products even in complex matrices, the use of those tech-
niques would have been advantageous.196–198  
3.3.3 Fermentation & extraction of Streptomyces sp. Tü2700 
Initially, Streptomyces sp. Tü2700 has been cultivated on small scale in 10 ml culture volume 
in 100 ml shake flasks with spiral and baffler, leading to 10 mg CFS extract. In order to obtain 
larger amounts of extract, necessary for further purification and structure elucidation, Strep-
tomyces sp. Tü2700 was cultivated at a larger scale in a labour-efficient manner, using a con-
tinuous stirred tank B20 bioreactor (B. Braun, Melsungen, Germany). 
Streptomyces sp. Tü2700 was cultivated according to 2.2.4. Samples were taken every 24 h, 
and CFS extracts were prepared as described in 2.4.2. Subsequently, these extracts were ana-
lysed using the S. aureus PC322 assay (see 2.3.2). During the course of the fermentation, the 
pH decreased slightly from initially 7.5 to 6.6 after 4 days. 
The halo size increased during the first three days up to 2.7 cm. After 4 days, the halo size 
remained constant at 2.7 cm. Hence, the fermentation was stopped after 4 days. Even though 
5 ml of polyethylene glycol had been added to the batch during the fermentation, excessive 
amounts of foam have formed which got partly lost, decreasing the yield to only 18 l culture 
broth. After filtration, 14 l CFS were obtained. Finally, extraction with ethyl acetate resulted 
in 3.8 g crude extract (see 2.4.4). 
This fermentation has shown that it is possible to cultivate Streptomyces sp. Tü2700 in a 
20 l scale in a bioreactor, maintaining its capability to produce the QS inhibiting compound. 
Moreover, 3.8 g of crude extract, containing substantial amounts of the active compound, 
could be obtained, which are necessary for further purification and structure elucidation. How-
ever, knowledge of the chemistry of the active compound could be used for further optimiza-
tion of the fermentation, in order to increase the amount of active compound. Moreover, in 
future fermentations in a bioreactor, the addition of sufficient amounts of PEG or other suita-
ble anti-foam agents is advisable to prevent loss of CFS through excessive foam formation.  
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3.3.4 Chromatographic isolation 
3.3.4.1 SephadexTM LH-20 
A well-established method for the isolation and separation of peptides, but also for other small 
molecules like terpenoids and lipids, is size-exclusion chromatography.199–201 For separations 
of low molecular weight peptides (~35 aa residues), SephadexTM LH-20 is often used as sta-
tionary phase in combination with water or mixtures of water and miscible solvents like 
MeOH.202 SephadexTM LH-20 is a beaded cross-linked hydroxy-propylene dextrane that exhibits 
at the same time hydrophilic as well as hydrophobic properties.202 It swells in water and also 
in numerous organic solvents. The separation principle is mainly based on size exclusion, while 
the exclusion limit depends on the solvent(s) used for swelling. However, due to the am-
phiphilic character of the material also adsorption effects play a role during the separation.202 
Initially, a pilot column of 2.5 cm x 78 cm filled with SephadexTM LH-20 as stationary phase and 
MeOH as mobile phase has been used to determine the purification parameters for the bioac-
tive compound (see 2.6.2). Using this column, 0.2 g of the crude extract have been fraction-
ated, and fractions have subsequently been subjected to a bioassay, since this was the only 
established method of detection for the bioactive compound. As a result, two bioactive frac-
tions could be detected. One, eluting after 11.5 h showing hazy, not stained halos, and the 
second one, eluting after 31 h, exhibiting clear halos. Additionally, all bioactive fractions have 
been analysed via HPLC. A comparison of the UV- spectrum of the antibiotic compound with 
the in-house database revealed accordance with the known isoflavone genistein. It has been 
shown that this compound can act as a topoisomerase II inhibitor and also exhibited antibac-
terial activity against S. aureus.203,204 Due to its low molecular weight of 270.2 g/mol, it was 
able to interact with the pores of the stationary phase, resulting in a tR of 31 h. Genistein is a 
natural product that can be found in plants including lupin and coffee plants as well as in soy 
beans.205,206 Even though Actinobacteria are able to produce isoflavonoids, it is most likely that 
genistein originates from the cultivation medium, since Streptomyces sp. Tü2700 has been cul-
tivated in NL19 media, which contains 2 % soy flour (see Table 3).207 For the samples containing 
the putative QS inhibitory compound, none of the UV-spectra of the respective peaks matched 
to the spectra in the in-house database. However, fraction 24 putatively contained only one 
compound, since it showed a single significant peak at a tR of 9.2 min  (see 2.6.4; Table 7), 
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exhibiting UV maxima at 230 nm and 280 nm with shoulders at 265 and 285 nm. This sample 
was subsequently submitted to HPLC-ESIMS analyses (see 2.6.4; Table 8) in order to determine 
the molecular mass of the compound. This analyses revealed a m/z [M+H]+ of 656. MS analyses 
also revealed impurities in the sample. Therefore, it was necessary to perform further purifi-
cation steps using different chromatographic methods, e.g. pHPLC. Moreover, these initial 
separations using the pilot column have confirmed the benefit of using SEC with 
SephadexTM LH-20 as stationary phase as an initial chromatographic step for the separation of 
the crude extract of Streptomyces sp. Tü2700. 
 
Figure 6. (A): HPLC-DAD chromatogram of extract A after purification using SephadexTM LH-20 
chromatography at 280 nm, exhibiting a significant peak at tR = 9.2 min; (B) UV-Spectrum at 
tR = 9.2 min, exhibiting maxima at 230 nm and 280 nm with shoulders at 265 and 285 nm 
In order to increase the operational capacity, a wider column (5 cm x 95 cm) was used to frac-
tionate the remaining 3.6 g of crude extract (see 2.6.2). As in-process control, all bioactive 
fractions have been analysed via analytical HPLC (see 2.6.4; Table 6). Fractions containing only 
a single peak were combined separately. All remaining bioactive fractions have also been com-
bined. Finally, the two extracts were dried under reduced pressure, resulting in 20 mg of an 
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extract, exhibiting a single peak (A) and 200 mg of an extract whose chromatogram shows 
multiple peaks (B).  
The three most pronounced peaks in extract B (1 (tR  = 7.5 min), 2 (tR = 8.5 min) and 
3  (tR = 9.2 min)) as well as the single peak in extract A (tR of 9.2 min) exhibit the same  
UV-spectra with maxima at 230 nm and 280 nm (see Figure 6). HPLC-ESIMS analysis revealed 
m/z values of [M+H]+ 674 for 1 and [M+H]+ 656 for 3. The data for compound 2 are ambiguous. 
Due to their comparable behaviour during the separation, and the fact that all three com-
pounds feature a similar UV- spectrum, it is tempting to speculate that these compounds share 
the same chemical scaffold. The mass difference of 18 could be due to the loss or addition of 
one water molecule (e.g. as the result of a hydrolysation reaction of an intramolecular ester 
or ether bond). 
3.3.4.2 pHPLC 
In order to isolate the bioactive compound from extract A, preparative HPLC was applied, since 
the compounds could be separated already during analytical HPLC with a good resolution. 
Therefore, based on the initial analytical method (Table 6) a suitable preparative method has 
been developed. 
It was necessary to scale up the analytical method from the Phenomenex 
Luna C18 250 x 4.6 mm column to the respective semi-preparative column with 10 mm inner 
diameter (see Table 16). Therefore, the flow was increased from 2 ml/min to 9.45 ml/min. Af-
ter optimization of the gradient in terms of time efficiency and peak resolution, the best 
method for the isolation of the single compound proved to be an isocratic mixture of 
60 % water and 40 % ACN without any modifiers for 10 min. The tR of the bioactive compound 
was 7.2 min. This method yielded in 8 mg of a pure compound from extract A. 
The whole isolation scheme of this bioactivity guided isolation, starting from the culture fil-
trate and ending with the pure compound, is depicted in Figure 7.  
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Figure 7. Isolation scheme for oxazolomycin. 
3.3.5 Identification of oxazolomycin A 
Dereplication is a crucial step for the identification of NPs.197 The aim of dereplication is to 
identify already known compounds as quickly as possible in order to avoid time consuming 
isolation and structure elucidation processes. Thus, dereplication should be performed as 
early in the process and with as many data in hand as possible. During this study, the bioactive 
compound could not be dereplicated before isolation, using the in-house HPLC-MS and  
UV databases. 
After isolation of the bioactive compound (3) (see section 3.3.4.2) from extract A, it was ana-
lysed using HR-MS (2.6.5). This method confirmed on one hand the purity of the isolate, and 
on the other hand it indicated an accurate mass of m/z [M+H]+ of 656,35435. These data were 
used to calculate molecular formulae, using the Universal mass calculator tool. This calculation 
led to 4 different formulae with mass accuracies less than 1 ppm, C35H50N3O9+, C34H44N10O4+, 
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C20H46N15O10+, C21H52N8O15+. A repetition of the search in the dictionary of NPs using the neu-
tral molecular formulae, showed no entries except for the formula C35H49N3O9, revealing oxa-
zolomycin A as compound having this molecular formula. 
In order to confirm that the compound isolated from extract A is truly oxazolomycin A or a 
member of this family, UV spectra of oxazolomycin A and the isolated compound were com-
pared. The UV spectrum of oxazolomycin A shows maxima at 265 (e, 28000), 275 (e, 34000), 
and 285 nm (e, 27000) due to the triene system, and one maximum at 230 nm due to the 
conjugated diene chromophore.208 As described above (see section 3.3.4.1) the spectrum of 
the isolated compound exhibits UV maxima at 230 nm and 280 nm with shoulders at 265 and 
285 nm. Therefore, additionally to potentially sharing the same molecular formula, both com-
pounds feature the same UV absorption pattern. 
To finally prove that both compounds are identical, 3 was dissolved in MeOH-d4 and a proton 
NMR spectrum was recorded (see section 0) (see Figure 8). Comparison of the 1H NMR spec-
trum with literature data revealed that all observed signals were consistent with those previ-
ously described.209 Therefore, 3 was confirmed to be indeed oxazolomycin A. Compound 1 
showing a m/z [M+H]+ difference of 18, while exhibiting the same UV- spectrum of 3 is most 
likely a derivative of oxazolomycin A, which potentially contains an additional hydroxyl group. 
 
Figure 8 1H NMR spectrum of oxazolomycin A (400 MHz; methanol-d4), grey- shaded areas 
are residual solvent signals of methanol-d4 
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Figure 9 Structures of oxazolomycins. Adapted from Moloney et al. (2004) 
Oxazolomycin A was first described in 1985. It was found during a screening campaign for new 
NPs from Streptomyces sp. with inhibitory activity against Ehrlich ascites tumour.210 However, 
Mori et al. noted, that the compound that they described as oxazolomycin might be identical 
to a compound described in 1971 as resistaphylin.210,211 Since the structure of resistaphylin has 
not been determined at this time, Mori et al. findings are considered being the first report of 
oxazolomycin.211 It has become the parent and eponymous member of a growing group of NPs 
(see Figure 9) that have all been isolated from several Streptomyces species. Characteristic for 
this group of NPs is the unusual spiro fused β-lactone/γ-lactam linked via a triene and  
(E,E’)-diene spacer to an oxazole terminal residue. Variations occur either in the geometry of 
the triene double bond (oxazolomycins A-C) or the substituents of the β-lactone ring (curro-
mycin A, B and 16-methyloxazolomxcin).208 
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The oxazolomycins exhibit wide ranging antibiotic activity against Gram positive bacteria like 
Bacillus subtilis (e.g. 16- methyloxazolomycin, MIC = 5 µg/ml), and also antiviral activity 
against vaccinia, herpes simplex type I, and influenza A.208,212,213 Additionally, the oxazolomy-
cins have shown activity as in-vivo antitumor agents (LD50 = 10.6 mg/kg for intraperitoneal 
injection in mice).208 Moreover, these compounds have been described as novel plant trans-
formation inhibitors upon infection with Agrobacterium tumefaciens.214,215 Only limited bio-
logical studies on the MoA of the oxazolomycin A have been performed.216,217 In an artificial 
lipid membrane model, it has been shown that oxazolomycin A is a protonophore at  
pH 4.7 - 7.0, and thus increases membrane conductivity. Above pH 7.5 it is able to convey pro-
tons as well as monovalent cations like potassium.217 It can be assumed that the bioactivities 
of oxazolomycin A are correlated with these ionophoric properties. 208 In case of the antiviral 
activity, these drugs inhibit the membrane fusion mediated by haemagglutinin by raising the 
pH of the normally acidic endosomes, like amantadine, which is an approved drug for the treat-
ment of influenza. The membrane fusion with the host cells is a crucial step within the viral 
life-cycle, since it leads to the dispersal of the viral RNA into the host cell cytoplasm.208 In re-
gard to their cytotoxic and antibacterial behaviour, it is most likely that the activity is related 
to the membranophilic behaviour of the oxazolomycins. However, this needs to be further in-
vestigated.208 
 
Figure 10. Results of the bioactivity assays of oxazolomycin A against S. aureus PC322; 1-3: 
oxazolomycin A [c = 50 µg/ml]; H: hamamelitannin [c = 2 mg/ml]; D: DMSO; M: MeOH A: Assay was 
performed as usual (see 2.3.2), using X-Gal, resulting in hazy, less stained halos with a diameter of 
22.0 mm. B: A: Assay was performed as usual (see 2.3.2), but without using X-Gal, resulting in hazy, 
halos with a diameter of 22.0 mm, indicating antibacterial behaviour of oxazolomycin A.  
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So far oxazolomycin A is solely known for its antiviral, cytotoxic and antibacterial behaviour, as 
well as its potential to inhibit plant transformation. In order to analyse its antivirulence activity, 
the S. aureus lacZ reporter assay monitoring transcriptional activity of the hla promoter has 
been performed with a 50 µg/ml solution of the isolated oxazolomycin A as described in 2.3.2. 
As a result, hazy, less stained halos with a diameter of 22.0 mm occurred (see Figure 10). In 
parallel, the same assay was performed with a 50 µg/ml solution of the isolated oxazolomy-
cin A, but without X-Gal. Exclusive reduction of the hla expression in S. aureus would cause no 
inhibition zones, since bacterial growth should not be affected. However, the wells containing 
the oxazolomycin A solution were surrounded by hazy halos with a diameter of 22.0 mm 
(see Figure 10). This experiment confirms that oxazolomycin A is not a QS inhibitor, but instead 
exhibits partial antibacterial activity against S. aureus PC322. This behaviour has never been 
described for oxazolomycin A, but is in accordance with reports about the bioactivity of its 
methylated derivative KSM-2690 B (see Figure 9). According to the authors, this compound 
also showed hazy inhibition zones of 25.0 mm diameter at concentrations of 50 µg/ml against 
S. aureus Smith.218  
As already mentioned (see section 1.3.2), the assay utilized in this study has led to the identi-
fication of several compounds, interfering with the agr system, e.g. norlichexanthon, 
solonamide A & B, ngercheumicin F, G, H & I and savirin.148–150,219,220 Yet, so far no compounds 
except for glucose have been reported that decrease the expression of hla independently of 
agr.221,222 Oxazolomycin A and presumably also KSM-2690 B appear in the assay as QS inhibi-
tors by exhibiting hazy less stained halos. Through only partly inhibited bacterial growth, halos 
still appear hazy, and due to the reduced cell number also less stained. Hence, it can be as-
sumed that all compounds, which not entirely kill S. aureus cells will interfere with this assay 
and can be considered as false positive hits. Therefore, in order to eliminate those compounds 
early in the screening process, it would be advisable to analyse every positive hit in a second 
assay. This second assay should be performed exactly as the usual S. aureus PC322 assay 
(see 2.3.2), but without supplementing X-Gal in the agar. Compounds interfering with bacterial 
growth will still result in halos. Compounds that are exclusively interfering with the expression 
of hla will cause no inhibition zones. 
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3.3.6 Genome analysis 
To analyse the capability of Streptomyces sp. Tü2700 to produce oxazolomycin, its genomic 
DNA was isolated (see 2.9) and subsequently fully sequenced. It was obtained as one single 
contig, comprising 8,019,152 bp with a GC content of 72.0 %. For the identification of biosyn-
thetic gene clusters, the sequence was submitted to the antibiotics and Secondary Metabolite 
Analysis Shell (antiSMASH).223 In total, 28 clusters have been identified. Of these, 6 clusters 
showed  ≥ 90 % similarity to already characterized clusters. Among these are biosynthetic gene 
clusters (BGC) for compounds widespread amongst bacteria like the osmolyte ectoin, the ca-
rotenoid isorenieratene, the sesquiterpene albaflavenon, the membrane constituent hopene 
and the peptide siderophore coelichelin, but also a BGC having 90 % similarity to the known 
cluster of oxazolomycin. For a more profound insight into the resemblance of the respective 
genes, the genome analysis was complemented with manual BLAST analyses (see Table 22).190 
It revealed the presence of homologues to all genes that have previously been annotated as 
ozm genes in the oxazolomycin (ozm) BGC, being also arranged in the same way as in the 
ozm gene cluster.224,224  
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Table 22. Results of the BLAST analysis – comparison of the ozm gene cluster of S. albus JA3453 
and the putative oxazolomycin gene cluster of S. sp. Tü2700 224 
Gene 
AA Identity 
[%] 
AA Similarity 
[%] 
AA Gaps 
[%] 
Annotation/ Proposed function 
512084 to 513457 94 97 0 ozmA   (Antibiotic efflux protein) 
510941 to 512041 91 93 0 ozmB   (Glyceryltransferase/ 
               phosphatase) 
509988 to 510941 96 97 0 ozmC   (Acyltransferase) 
508849 to 509943 92 94 0 ozmD   (Acyl-dehydrogenase) 
508578 to 508853 96 95 1 ozmE    (ACP) 
507898 to 508560 92 96 0 ozmF    (O-Methyltransferase) 
507035 to 507895 90 93 0 ozmG    (3-Hydroxyacyl-CoA- 
               dehydrogenase) 
487455 to 505880 83 86 2 ozmH   (Hybrid NRPS/PKS) 
473236 to 479409 85 87 2 ozmJ     (PKS) 
469644 to 473216 86 88 1 ozmK    (PKS) 
463567 to 469563 90 93 0 ozmL    (NRPS) 
460391 to 463507 87 90 1 ozmM  (Acyltransferase/ 
                oxidoreductase) 
451545 to 460241 82 85 2 ozmN    (PKS) 
441772 to 443862 85 89 0 ozmO    (NRPS) 
440473 to 441618 97 98 0 ozmP     (Unknown) 
438034 to 440460 86 90 0 ozmQ    (PKS) 
435537 to 436403 90 95 0 ozmR    (Transcriptional regulator) 
434858 to 435490 95 95 0 ozmS     (Transporter) 
433544 to 434836 87 93 0 ozmT     (Thr-tRNA synthetase) 
429651 to 432455 91 92 0 ozmU    (Transcriptional activator) 
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3.3.8 Stability testing 
Stability of the bioactive compounds and the drug product is a crucial parameter in drug de-
velopment, since it has an influence on the storage conditions and the shelf life.  
In order to examine the stability of 3, stress tests evaluating parameters which are known to 
enhance degradation reactions using the pure compound dissolved in MeOH at a concentra-
tion of 1 mg/ml have been performed (see 2.7). Those parameters are light, since it is known 
to trigger radical reactions like substitution, addition, or polymerisation; oxygen, due to its 
potential to act as initiator of radical reactions; and temperature, since it is a crucial parameter 
and general accelerator of degradation reactions. 
Figure 11. Results of the stability testings of oxazolomycin A. This graphic depicts the concen-
tration [%] of oxazolomycin A [1mg/ml in MeOH] under different storage conditions. The control sam-
ples were stored at atmospheric conditions, at ambient temperature, and not protected from light. 
Unless otherwise stated, all other samples were stored under exclusion of light in an argon atmosphere 
at ambient temperature (23 °C). One of these parameters was changed at a time, “- Ar” indicating, an 
air atmosphere, “+ Light” indicating samples with light exposure, 4 °C/60 °C indicating variations in the 
storage temperature. Samples were analysed after 17 h, and 77 h of storage.  
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At the beginning of the study, all samples have been evaluated via HPLC-UV. All samples were 
prepared as triplicates. The samples were stored under the respective conditions and analysed 
again after 17 h (~ 1 d) and 77 h (~ 3 d). Finally, the maximum peak heights at 280 nm were 
compared. The Degradation [%] was calculated according to formula (1).  
The results were ambiguous since e.g. the control samples that were neither protected from 
light, nor oxygen and stored at ambient temperature were less prone for degradation after 
77 h than the samples that were protected from light and oxygen and stored at 4 °C. However, 
a trend is noticeable, since, after 77 h, all samples showed a degradation of 10 - 20 % (see Fig-
ure 11). Light exposure and an increased temperature might lead to an increased degradation 
process. The concentration of the samples stored at 60 °C decreased after 17 h already to 
74.7 %, reaching 68.2 % after 77 h (see Figure 11).  
In the chromatograms, except for those of the samples that were stored at 60 °C, no degrada-
tion products became visible (no appearance of additional peaks). An additional peak only 
appeared in the samples stored at 60 °C. HPLC-MS analysis (see 2.6.4; Table 8) of these sam-
ples revealed that this additional peak has a m/z [M+H]+ of 688, which is an increase in weight 
by 32. Since 3 was dissolved in MeOH, a transesterification of the β-lactone substructure of 
oxazolomycin A with MeOH via nucleophilic substitution could be the reason for the degrada-
tion, leading to the opening of the β-lactone ring and the addition of a MeOH molecule 
(see Figure 11). 
 
Figure 12. Putative ring opening and transesterification of the β-lactone substructure of ox-
azolomycin A via nucleophilic substitution with MeOH during the stability tests at 60 °C 
The ring opening of the β-lactone is likely to occur via nucleophilic substitution, in which the 
nucleophile MeOH attacks the sp2 carbonyl to form a tetrahedral intermediate which subse-
quently leads to the ring opening.225 These reactions are usually either acid or base catalysed. 
In view of the known pKa values for oxazole (0.8) and isoxazole (3.0), these two substructures 
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exhibit weak basic properties. Thus, mild basic conditions within the pure oxazolomycin A sam-
ples can be expected.226 Since transesterifications are known to be temperature and pressure 
dependent, an increased storage temperature of 60 °C could indeed accelerate the degrada-
tion of oxazolomycin A.227 However, in order to finally prove this hypothesis, further analysis 
of the by-product is necessary to confirm its structure. 
Even though instabilities of oxazolomycin derivatives have been reported, this is the first time 
stability tests have been performed with oxazolomycin A.218 Due to their earlier mentioned 
ambiguous outcome in regard of the control samples, it would be beneficial to repeat these 
experiments with a larger batch size and with more sampling time points. Additionally, since 
humidity is another crucial parameter for stability, its influence on the stability of oxazolomycin 
A would also be worth to examine. Unfortunately, these experiments could not be performed 
in the scope of this thesis, since the compound was completely degraded after a few weeks 
even though it was stored under light protection in an argon atmosphere at 8 °C. 
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3.4 Streptomyces sp. Tü2401 
3.4.1 Taxonomy 
Comparison of the 16S-rRNA sequence of strain Tü2401 with the NCBI database using the Basic 
local-alignment search tool (BLAST) revealed a number of sequences with > 99 % sequence 
identity, all belonging to the genus Streptomyces.190 Therefore, it can be assumed that strain 
Tü2401 is also a member of the genus Streptomyces. However, this method is insufficient to 
assign Streptomyces sp. Tü2401 to a specific species. 
Therefore the genomic DNA was isolated (2.9) and subsequently, the whole genome was se-
quenced using single-molecule real-time (SMRT) sequencing, also known as PacBio sequenc-
ing, honouring its developer Pacific BioSciences (PacBio). Finally, for the de-novo assembly of 
the sequence, the software FALCON was used to identify and connect overlapping contig ends. 
In order to automatically generate a species phylogeny with reference organisms, the se-
quence was submitted to the autoMLST program.191–193 As a result, the strain Streptomy-
ces globisporus C-1027 was identified as the closest relative with an estimated average nucle-
otide identity (ANI) of 92.0 % (Mash distance: 0.0803). These results confirm the strain Strep-
tomyces sp. Tü2401 as a member of the genus Streptomyces, being a close relative to Strepto-
myces globisporus C-1027 (Figure 13) 
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Figure 13. Phylogenetic tree of S. sp. Tü2401 (blue font) inferred from gDNA sequence using the 
soft-ware autoMLST. The phylogeny is rooted with Actinospica acidiphila NRRL B24431 (red font), 
strains depicted in green font represent type strains.  
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3.4.2 Primary screening 
The primary screening aimed at the analysis of the biosynthetic potential of Streptomy-
ces sp. Tü2401 in silico (see 3.4.3.1), as well as in vivo (see 3.4.4.1 & 3.4.5.3). Another crucial 
part of the primary screening is dereplication of the bioactive compound(s), in order to identify 
already known compounds prior to time-consuming isolation efforts.   
3.4.2.1 Biological activity 
In the initial agar-plug based screening (see section 3.1) against the Gram-positive S. au-
reus PC322 (see 2.3.2), Streptomyces sp. Tü2401 was highly bioactive with clear inhibition 
zones (> 2 cm), indicating no QS inhibition, but antibiosis. Subsequent bioactivity assays of 
Streptomyces sp. Tü2401 grown on ISP2 agar as well as in submerse cultures against the also 
Gram-positive B. subtilis 168 and the Gram-negative E. coli K12 (see 2.3.1) revealed additional 
antibiotic effects (> 2 cm) against those microorganisms. 
The antibiotic class of aminoglycosides is known to be produced by Actinobacteria and active 
against Gram-positive and Gram-negative bacteria likewise.228 These compounds are particu-
larly hard to identify in classical screenings, since they are highly hydrophilic and most often 
do not contain a chromophore.228 Therefore, in order to rule out that the bioactive com-
pound(s) belong to the aminoglycosides, S. sp. Tü2401 culture broth has been tested against a 
series of E. coli strains. Those strains harbour one or more resistance genes that decrease their 
susceptibility towards various antibiotics, including aminoglycosides like streptomycin, spec-
tinomycin, neomycin and gentamicin (see Table 23). Constant activity against all tested strains 
indicated that the resistance genes present in the tested E. coli strains did not confer re-
sistance against the compound(s) produced by S. sp. Tü2401. Most of these resistances (see 
Table 23) enhance export or degradation of the particular antibiotic. However, some of them, 
namely rpsL150, gyrA91 and rpoB318 modify cellular targets.161,229 Decreased streptomycin 
binding is conveyed by rpsL150, through an altered 30S ribosomal subunit. Binding of nalidixic 
acid to the DNA gyrase is decreased by mutation of gyrA91. Additionally, rifampicin binding to 
the DNA dependent RNA-polymerase is decreased by mutations of rpoB318.161 Since the via-
bility of none of those strains is improved, S. sp. Tü2401 presumably produces a compound 
with an alternative MoA.    
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Table 23. List of strains tested against S. sp. Tü2401, indicating their mutations and resistances 
Name Mutation Resistance 
E. coli K12  /  / 
E. coli H5434 yebA::cam yibP::spc streptomycin, 
chloramphenicol, 
spectinomycin 
E. coli H5309 araD139 D(argF lac)U169 rspL150 relA1 
flbB5301 deoC1 ptsF25 rbsR aroB 
fiu::MudX feoB::Tn5 corA::Tn10 
streptomycin, am-
picillin, neomycin, 
tetracyclin 
E. coli H5313 araD139 D(argF lac)U169 rspL150 relA1 
flbB5301 deoC1 ptsF25 rbsR aroB 
entC::MudX ftnspc 
streptomycin, 
spectinomycin, 
ampicillin 
E. coli JF486 
ara-55 delta(lac)3 thi-1 asnB::50 nagB2 
gyrA91 relA1 spoT1 asnA31 rpoB318 
nalidixic acid, ri-
fampicin 
E. coli BL21 B F– ompT gal dcm lon hsdSB(rB–mB–
)[malB+]K-12(λS) 
gentamicin 
E. coli BL21pWBT B F– ompT gal dcm lon hsdSB(rB–mB–) 
[malB+]K-12(λS) 
gentamicin 
S. aureus PC322 hla::lacZ  / 
B. subtilis 1S34 pHJS105-yorB-lacZ2  / 
In order to get deeper insights into the MoAs of the compound(s) produced by S. sp. Tü2401, 
bioactivity assays using B. subtilis 1S34 pHJS105-yorB-lacZ2 (see 2.3.3) revealed that cultures 
grown on solid medium, but not submerse cultures are able to induce the yorB reporter sys-
tem. However, antibacterial activity in the reporter system was shown to be present regard-
less of the growth conditions of S. sp. Tü2401. In previous studies, yorB was found to be up-
regulated during flourquinolone treatment.161,230 Additional studies strengthened the hypoth-
esis that the upregulation of yorB is a stress response triggered by inhibition of the topoiso-
merase IIα subunit, causing DNA damage.161,230–232 Nonetheless, the identification of other 
inducers of the yorB reporter system with diverse MoA indicate (see Table 24) that this re-
porter system is appropriate for the identification of compounds interfering with bacterial 
DNA or DNA replication in general. Therefore, it is most likely that S. sp. Tü2401 is, when grown 
on agar, producing a compound with either of these or even both as its target(s).  
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Cultures from S. sp. Tü2401 both grown on agar as well as submerse culture have been ana-
lysed in the yorB reporter assay, but only the cultures grown on agar were able to induce the 
yorB reporter system, while the others only showed antibiosis. Therefore, it is likely that 
S. sp. Tü2401 is producing at least two different compounds with different MoA, but similar 
activity spectra. The significance of the growth conditions of Actinobacteria on their secondary 
metabolite production is well known and has been aforementioned (see 1.2).30 
Table 24. Inducers of the yorB reporter system. Substances with determined MoA that induce the 
yorB reporter system in B. subtilis.161,230,232 (Adapted from Schneider et al. 2018) 
MoA  Compound Origin 
RNA polymerase inhibition  8-Hydroxyquinoline  Synthetic 
 Juglone  Carya illinonensis 
DNA gyrase inhibition   Novobiocin S. niveus 
DNA strand breaking  Alternariol monomethyl ether Alternaria sp. 
 Bleomycin  S. verticillus 
 Myxin Sorangium sp. 
 Phleomycin S. verticillus 
 Streptonigrin  S. flocculus 
DNA intercalation  Chromomycin  S. griseus 
 Daunorubicin  S. peucetius 
 Doxorubicin  S. peucetius 
DNA binding  Anthramycin  S. refuineus 
 Desmethylethersibiromycin Streptomyces spp. 
DNA crosslinking  Porfiromycin S. ardus 
S. sp. Tü2401 is a noticeable example of the genus of Actinobacteria and their huge potential 
of producing diverse bioactive secondary metabolites (see also 1.2).  
3.4.2.2 Comparison of production media  
In order to determine the best production medium for the hydrophilic metabolites from sub-
merse cultures, S. sp. Tü2401 was cultivated in NL200, NL300, NL500 and OM complex media 
(composition see Table 3) for seven days. The CFS was analysed after 4 and 7 days in standard 
E. coli K12 agar diffusion bioassays (see 2.3.1). Most samples revealed halos of more than 1 cm. 
CFS of NL500 after 7 d and CFS of OM after 4 & 7 d showed the biggest zones of inhibition  
(> 1.5 cm).161 Due to these findings, OM was considered to be the best production medium, 
80 3 Results & Discussion 
since it already exhibited the largest inhibition zones already after 4 days. Therefore, all further 
experiments were performed with CFS of cultures grown in OM for four days. 
3.4.3 Genome analysis 
To investigate the biosynthetic potential of Streptomyces sp. Tü2401, its genome was se-
quenced and analysed. Therefore, the genomic DNA of S. sp. Tü2401 was isolated, sequenced 
and aligned as described in 3.4.1. The final sequence consists of 8,139,204 base pairs with a 
GC content of 71.4 % allocated to 5 contigs.   
3.4.3.1 Identification of putative biosynthetic gene cluster 
In order to identify known biosynthetic gene clusters (BGC), the whole sequence was analysed 
using the antibiotic and Secondary Metabolite Analysis SHell (antiSMASH 4.0.2).233 In total 
26 clusters have been identified throughout the genome, including 7 that show a similarity of 
≥ 95 % to already characterised BGC (see Table 25).  
Table 25. Output of antiSMASH analysis of S. sp. Tü2401, showing BGC with ≥ 95 % similarity 
to known biosynthetic gene clusters  
Cluster Type Most similar known cluster Similarity [%] 
4 Bacteriocin-T1 PKS-NRPS Frontalamide, Heat-Stable 
Antifungal Factor 
100 
10 Lanthipeptide AmfS 100 
14 Terpene Isorenieratene 100 
17 NRPS Griseobactin 100 
21 Ectoine Ectoin 100 
24 Siderophore Desferrioxamine B 100 
26 T1 PKS-NRPS C-1027 100 
As cluster 4 the software detected a Type1-PKS-NRPS hybrid cluster containing genes with high 
similarity to genes known from the frontalamide BGC (BGC0000996) and the heat-stable anti-
fungal factor (HSAF) BGC (BGC0000999).234,235 The frontalamides and the HSAF both share the 
same structural feature of polycyclic tetramate macrolactams (PTMs) (see Figure 14). Fronta-
lamide A & B and also the HSAF are on the one hand known for their antifungal bioactivity, a 
common MoA among bacterial PTM, and on the other hand for their activity against plant 
pathogens like Bipolaris sorokiniana, Fusarium graminearum, F. verticilloides and Ophiostoma 
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minus.234–238 PTM gene clusters could be identified in more than 50 % of the sequenced Strep-
tomyces species and are highly conserved.234 However, the PTM clusters have been also iden-
tified in a broad variety of other bacterial families, for example in the Gram-negative Xan-
thomonadaceae.161,234,239  
 
Figure 14. Structures of polycyclic tetramate macrolactams (PTM). Adapted from Mo et al.    
(2014).238 
The existence of a PTM cluster in the genome of S. sp. Tü2401 implies its potential to produce 
antifungals. However, neither has this bioactivity been tested yet, nor could frontalamide A, B 
or HSAF been identified in the supernatant via HPLC-DAD or HPLC-MS. 
Cluster 10 was identified by antiSMASH as lanthipeptide BGC, at which the genes show high 
similarity to the AnfS BGC (BGC0000496). The peptide AmfS is considered being an extracellu-
lar morphogen without any anti-infective bioactivity. The amf gene cluster has been identified 
as a regulator of the initiation of aerial-mycelium formation in Streptomyces griseus.161,240 
A terpenoid cluster has been predicted by antiSMASH as cluster 14. The genes showed high 
homology with an isorenieratene BGC, originally identified from Streptomyces griseus 
(MIBiG BGC-ID: BGC0000664).161 Isorenieratene (see Figure 15) is an extensively conjugated 
compound, belonging to the carotenoids. Even though the biological function of isorenier-
atene in Actinobacteria is still unknown, it has been speculated that it is a response to blue or 
UV light, due to its large conjugated system.161,241,242 However, neither the bacteria them-
selves, nor the culture broth took on the orange colour, which is typical for carotenoids. There-
fore, either this cluster was not expressed under the cultivation conditions, or the cluster was 
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expressed, but the amount of biosynthesised isorenieratene had no impact on the appearance 
of S. sp. Tü2401. 
 
Figure 15. Structure of isorenieratene 
Cluster 17 was predicted by antiSMASH to be a NRPS cluster. The genes were almost identical 
to a griseobactin BGC (BGC0000368) from Streptomyces sp. ATCC 700974. Griseobactin is a 
siderophore produced under iron limitation (see Figure 16). Typical siderophores synthesised 
by Streptomyces sp. are desferrioxamines.243 However, other structurally different sidero-
phores, coproduced with desferrioxamines have been reported, namely coelichelin in Strepto-
myces coelicolor, enterobactin in Streptomyces tendae, and the catechol-peptide griseobactin 
from Streptomyces sp. strain ATCC 700974 and some strains of Streptomyces griseus.161,244,245 
 
Figure 16. Structure of griseobactin 
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Since it has been described that aforementioned compounds are mostly coexpressed with des-
ferrioxamines, it is no wonder that antiSMASH predicted another siderophore cluster as cluster 
24.245 Its genes are identical to the desferrioxamine B BGC from Streptomyces griseus 
(BGC0000941).161,246 As mentioned above, desferrioxamine B (see Figure 17), like griseobactin, 
is required for iron uptake especially under starvation conditions.247  
 
Figure 17. Structure of desferrioxamine B 
The BGC of ectoin, another compound that is widespread among several species of bacteria 
and also within the family of Streptomyces, has been predicted to be on cluster 21.248  
Ectoin (see Figure 18) serves as an osmolyte preventing especially halophilic bacteria from 
osmotic stress.249 
 
Figure 18. Structure of ectoin 
Cluster 26 is the last cluster that shows a similarity of ≥ 95 % to an already characterised BGC. 
It has been predicted by antiSMASH to be a Type1-PKS-NRPS hybrid. The cluster showed se-
quence homology to the C-1027 BGC from Streptomyces globisporus C-1027 (BGC0000965). 
C-1027 belongs to the class of enediynes (see Figure 19) that is characterized by two acety-
lenic groups conjugated to a double bond within a nine- or ten-membered ring.250–252 This 
structural feature is the warhead of the enediynes, and its gene cassette organisation is highly 
conserved.253 Therefore, the identification of an enediyne gene cluster in the genome of 
S. sp. Tü2401, even though highly homologous to the cluster of an already known compound, 
is no proof that this strain produces indeed C-1027. It only emphasizes the potential of 
S. sp. Tü2401 to produce an enediyne. These compounds are known for their cytotoxic as well 
as for antimicrobial activities.254 By creating a transient 1,4- benzenoid diradical due to cyclisa-
tion of the enediyne ring, a highly reactive nucleophile is formed, which abstracts up to two 
hydrogen atoms from the DNA backbone (see Figure 20).254,255 These DNA radicals in turn can 
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cause interstrand crosslinks by reacting with another DNA radical, or create reactive oxygen 
species (ROS) by reacting with O2, which subsequently cause double- or single-stranded DNA 
cleavage.255,256 By exhibiting this MoA, enediynes could putatively induce the yorB reporter 
system of Bacillus subtilis 1S34 pHJS105-yorB-lacZ2. Enediynes are not known for inducing this 
system, which is most likely because they have never been tested in it, rather than because of 
inactivity. However, compounds causing double- or single-stranded DNA cleavage or inter-
strand crosslinking similar to the enediyne MoA have been shown to induce the yorB- induc-
tion assay.159,161 
The ten-membered enediyne compounds were identified as discrete compounds.161,253 On the 
contrary, the nine- membered enediynes have been found to be attached to a protein, often 
called apoprotein that presumably works as a stabilizer for the enediyne group, preventing 
them from self- decomposition as well as a carrier to the double-stranded DNA.252,257–259 
Therefore, they are also called chromoproteins.253,260 The compound C-1027 belongs to the 
group of nine- membered enediynes.250  
It is very likely that S. sp. Tü2401 is indeed producing an enediyne compound. Since antiSMASH 
predicted similarity only to the cluster of C-1027, extraction methods that have been success-
fully applied for this enediyne should be used for the isolation of the yorB- inducing compound 
produced by S. sp. Tü2401. 
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Figure 19. Structures of all enediyne compounds known to date and their respective year of 
identification (in parentheses). This compound family consists of (A) nine-membered ring compounds 
and (B) ten-membered ring compounds. The enediyne ring, which serves as their biological warhead, 
is highlighted in red. Even though sporolides, cyanosporolids and fijiolides do not contain this unique 
structural feature, they are presumably derived from nine-membered enediyne precursors due to 
their chlorine substitution pattern after cycloaromatization. Adapted from Shen et al. (2015)161,250  
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3.4.4 Agar extraction 
As mentioned above (see 3.4.2), the yorB- inducing compound is only produced when 
S. sp. Tü2401 is grown on solid media (ISP2 agar). Therefore, in order to identify the bioactive 
compound(s), it was mandatory to develop an extraction method from agar. 
As mentioned above, S. sp. Tü2401 features a gene cluster with sequence homology to a 
known enediyne BGC (see 3.4.3.1), i.a. C-1027. Thus, a protocol that had been successfully 
applied to the isolation of C-1027 has been used.160 However, this protocol was originally de-
veloped for the extraction of the compound from liquid culture, therefore in our case it was 
required to liquefy the agar prior to the isolation. According to the safety data sheet of the 
supplier (Sigma Aldrich), the melting point of the used agar was between 85 °C and 95 °C. 
Even the melting point of low melting point agarose was at 65.5 °C (Thermo Fisher Scientific). 
Extraction at these high temperatures could lead to an enhanced degradation of the com-
pounds of interest and has therefore not been tested. A second attempt to liquefy the agar 
prior to the isolation aimed at pressing the medium out of the gel structure. Hence, standard 
ISP2 agar plates (approx. 20 ml) were sliced and transferred into a 50 ml tube and subsequently 
centrifuged at 20,000 g for 30 min, resulting in 10 ml supernatant. The following procedure 
was adapted from Yan et al. (2018).160 After filtration trough a folded filter, the pH was adjusted 
to pH 4.0 using 0.1 M HCl. After centrifugation, (NH4)2SO4 was added to the supernatant up to 
the saturation point and incubated for 4 h at 4 °C. This step aimed at the denaturation and 
subsequent precipitation of the apoprotein as a complex with the chromophore. Afterwards, 
the precipitate was separated, dissolved in 10 ml 0.1 M K2HPO4 at a pH of 8.0 and finally ex-
tracted with 10 ml ethyl acetate. During this step, chromophore and apoprotein were finally 
separated. While the denaturated apoprotein remained as a pellet, the chromophore was dis-
solved in the organic phase. After drying under reduced pressure, the pellet was dissolved in 
2.0 ml MeOH.   
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3.4.4.1 Dereplication of the bioactive compound produced on solid medium 
In order to identify and dereplicate the yorB-inducing compound, the dissolved pellet obtained 
from the agar extraction (see 3.4.4) was submitted to HPLC-MS analysis. Since antiSMASH pre-
dicted 95 % cluster identity with the BGC of C-1027, the total ion chromatogram has been 
analysed for the presence of m/z 844.3 ((M+H]+ of C-1027).252 However, no matching mass 
could be identified in the chromatogram. 
    
Figure 20. Scheme of the spontaneous aromatization of C-1027 at room temperature via a 
Masamune−Bergman rearrangement (Adapted from Inoue et al. (2006))252,261 
During the isolation process, the apoprotein was denaturated and later separated from the 
chromophore. In several studies it has been reported that the chromophore without the apo-
protein is prone for self-decomposition and further degradation (see Figure 20), which is also 
likely to happen during isolation.262,263 Therefore, the chromatogram has been analysed in a 
second attempt in regard to the aromatized chromophore that should have a mass compared 
to the original chromophore of m/z +2. In fact, the corresponding mass of the aromatized 
C-1027 chromophore (m/z 846.3 [M+H]+ and also m/z 868.3 [M+Na]+) was detectable in the 
chromatogram. Additionally, the isotope pattern of the aromatized C-1027 chromophore in 
the spectrum was in accordance with literature data from Inoue et al. (2006) (see Figure 21).252 
The peak at m/z 847.3 represents most probably the aromatized C-1027 chromophores, where 
one 12C atoms has been substituted by one 13C atom. Since the natural incidence for 13C atoms 
is 1 %, the peak intensity for this molecule should be ca. 43 % of the parent ion, which is indeed 
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represented in the spectrum (see Figure 21). The peak at m/z 848.3 is probably the isotope 
peak were the 35Cl atom is exchanged by a 37Cl atom. The peak intensity should be due to the 
natural incidence ca. 1/3 of the parent ion peak. However, the peak intensity is increased to 
ca. 40 % which might be due to other substitution products, like for example a two atom sub-
stitution of 12C/13C atom (incidence 0.1 ‰) or a two atom substitutions of 1H/2H (inci-
dence 0.1 ‰) or a one atom substitution of 12C/13C and of 1H/2H. But also substitutions with 
other naturally occurring isotopes like e.g. 15N (incidence 0.36 %), 17O (incidence 0.37 ‰), 
18O (incidence 0.2 %) might contribute to the characteristic isotope pattern of C-1027. 
 
Figure 21. ESI-MS spectra of the aromatized C-1027 chromophore. (A) MS spectrum of the 
aromatized C-1027 chromophore after agar extraction. (B) MS spectrum of the aromatized C-1027 
chromophore according to Inoue et al. (2006)252 
Thus, these data confirm that S. sp. Tü2401 is indeed capable of producing an enediyne com-
pound, most likely C-1027.  
C-1027 was initially isolated from Streptomyces globisporus C-1027 in 1988, as a highly potent 
antitumor antibiotic.264,265 It showed exceptional cytotoxicity to cultured cancer cells 
(IC50 = 1.5 x 10-17 – 3.2 x 10-16 M) as well as against a panel of transplantable tumour cells in 
mice.265,266 
The C-1027 holoprotein consists of a labile chromophore, also called lidamycin that is, like 
most nine-membered ring enediynes bound noncovalently to its apoprotein (10489 Da).  
The chromophore is linked to the apoprotein via hydrophobic interactions between the hydro-
phobic groups (benzoxazine and the macrocycle) of the chromophore and the hydrophobic 
side chains of the apoprotein 252,256,267 In general, nine- membered ring enediyne compounds 
need an external activation by e.g. nucleophiles to initiate the electronic rearrangement that 
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leads to the aromatization via a Masamune-Bergman reaction. Except for maduropeptin and  
C-1027, once they are detached from their stabilizing apoproteins they spontaneously aroma-
tize at room temperature (see Figure 20) (T1/2 (C-1027) = 0.8 h in ethanol).252,268 That is why es-
pecially C-1027 has the highest reactivity within the enediyne family.252 It is causing multiple 
DNA damages including single- and double-strand breaks, abasic sides, alteration of cell cycle 
progression, induction of chromosomal aberrations and telomere dysfunction at a low nano-
molar concentration.266,269 The interplay between the benzoxazine moiety and the nine mem-
bered enediyne ring is the reason for the extreme toxicity. It has been shown through high-
resolution NMR studies of the complex of double-stranded DNA and aromatized chromophore 
that while the enediyne ring is placed in the minor DNA grove, the benzoxazine moiety is ori-
ented parallel to the DNA bases.252,270,271 The necessity of the benzoxazine moiety for DNA 
binding has been shown by Yu et al., since the absence of this moiety lead to a loss of binding 
affinity by ca. 400-fold.252,272 Moreover, it has been reported that interaction with the DNA is 
highly sequence specific. Accordingly, the following five-nucleotide sequences are prone for 
double-strand lesions CTTTT/AAAAG, ATAAT/ATTAT, CTTTA/TAAAG, CTCTT/AAGAG, and espe-
cially GTTAT/ATAAC (underlining the cutting sites).252,266,273 
The remarkable cytotoxic activities of many enediyne compounds have made them a promis-
ing target for drug candidates. However, the toxicity is not only extreme, but also delayed, 
which limits their application.268,274 Therefore, conjugation of enediynes with either polymers 
like e.g. poly(styrene-co-maleic acid) (SMA), or its derivatives, or monoclonal antibodies have 
shown great promise, as they improve uptake and toxicological profile at the same time.268 
Hence, when in 1994 the conjugate of neocarcinostatin and SMA (SMANCS®) has been ap-
proved for the treatment of hepatoma in Japan, it was the first enediyne drug used in clinics. 
This drug has also been successfully used for antitumor treatment in lung, stomach, pancreas, 
gall bladder, lymphoma, and melanoma in combination with Lipidol® - a lipid contrast agent.275 
Calicheamicin is another enediyne compound that is successfully employed in tumour ther-
apy. In an antibody-drug conjugate (ADC) with a CD33 monoclonal antibody (mAB) 
(e.g. Mylotarg®) it is used to treat acute myeloid leukaemia and as an ADC with a CD22 mAB 
(e.g. Besponsa®) for non-Hodgkin lymphoma.250,275,276 Furthermore, there are currently sev-
eral mAB-C-1027 conjugates against heptoma in phase II clinical trials in China.256,277–280 
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Given the fact that only 11 enediynes are structurally characterized to date, with four addi-
tional compounds that have only been isolated in the aromatized form yet, it is remarkable 
that 3 of these have already been used in clinics, representing a success rate of ca. 30 %.250 
Bioinformatic analysis of bacterial genomes have revealed that enediyne BGC are highly abun-
dant among Actinobacteria (6.3 %). Therefore, it is even more astonishing that the number of 
compounds belonging to this group is still small. 
The identification of C-1027 as a secondary metabolite of S. sp. Tü2401 on the one hand shows 
the great potential of the Tübingen strain collection to produce highly potent compounds. It is 
the first time an enediyne compound has been identified from the collection, but presumably 
not the only one. Taken into account, the abundance of 6.3 % of enediyne BGC among Actino-
bacteria genomes and the number of 1200 Actinobacteria strains comprising the Tübingen 
strain collection, it can be assumed that statistically 75 enediyne producing strains are yet to 
be identified.  
On the other hand, these findings also reveal that the yorB reporter gene assay is a powerful 
tool to identify enediyne producing strains. 
3.4.5 Purification of hydrophilic metabolites from S. sp. Tü2401 submerse 
cultures 
As mentioned above, S. sp. Tü2401 is capable of producing at least two different compounds 
with different MoA, but similar activity spectra, depending on the cultivation conditions. While 
the compound produced on solid medium is most probably the enediyne C-1027, the com-
pound produced in submerse culture remained unknown in the early process of dereplication 
due to multiple reasons. 
On the one hand, it was impossible to extract the compound(s) from the CFS into organic sol-
vents. Standard extraction protocols (see 2.4.6) employing various pH of the CFS (pH 2; 5; 7; 
9; and 11) and several organic solvents e.g. ethyl acetate, methyl acetate, ethyl formate, and 
butanol (data not shown) were unable to extract the active compound(s). The extraction suc-
cess was analysed using standard E. coli K12 agar diffusion bioassays (see 2.3.1). In all cases 
the aqueous phase remained active, while the organic extract was not bioactive (see Figure 
22). 
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On the other hand, standard RP-HPLC-DAD dereplication methods could not been applied, 
since the hydrophilicity of the compound(s) did result in almost no retention on different re-
versed phase HPLC columns (see Table 29). 
Moreover, the elution in the injection peak led to an overlay of signals, therefore, no signifi-
cant absorption in the DAD could be assigned to the compound(s). However, further analysis 
indicated that the compounds putatively lack chromophores and thus do not show any signals 
in the DAD at all. 
Due to these first observations, high hydrophilicity, and lack of chromophores, it was neces-
sary to develop an entirely new strategy for the isolation and identification of the bioactive 
compounds produced by S. sp. Tü2401 submers cultures. 
 
Figure 22. Results of E. coli K12 agar diffusion bioassays of OM CFS extracts of S. sp Tü2401. 
CFS of OM cultures of Streptomyces sp. Tü2401 were extracted with either (A) ethyl acetate, (B) methyl 
acetate or (C) ethyl formate. pH of CFS were adjusted prior to extraction to 2, 5, 7, 9 or 11. 50 µL of 
each phase were analysed in agar diffusion assay against E. coli K12. Aqueous phases were pipetted 
directly into the wells in the upper row (aq). Organic phases were applied to sterile filter discs and 
placed on the bottom row (org). (Adapted from Schneider 2018)161  
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Consequently, after cultivation of S. sp. Tü2401 in a 10 l fermenter (see 2.2.4), the entire cul-
ture was separated by multiple sheet filtration in CFS and mycelium, resulting in 8.5 l CFS 
(see 2.4.4). Subsequently, the CFS was extracted five times with each 2.0 l of EA. The organic 
phases were combined and concentrated under reduced pressure, resulting in 235 g crude 
extract (see 2.4.4.2).161 The aqueous phase was collected and lyophilized (see 2.5), resulting 
in 91 g reverse extract.161 Both crude and reverse extract were analysed for antibacterial activ-
ity against E. coli K12 in agar diffusion assays (see 2.3.1), revealing that only the reverse extract 
showed inhibition zones, while the crude extract was inactive. HPLC chromatograms of the 
reverse extract unveiled a substantial reduction of the number of peaks.161 Clearly, this first 
step of the isolation aimed at the removal of lipophilic compounds, dissolvable in EA. 
However, since S. sp. Tü2401 has been cultivated in a complex medium, besides the lipophilic 
compounds a plethora of hydrophilic compounds, e.g. sugars, salts, and amphiphilic metabo-
lites still remained in the reverse extract. 
Table 26. Results of the extraction of the reverse extract of S. sp. Tü2401. 
Solvent pH  
Inhibition zone after 
the 1st extraction [cm] 
Inhibition zone after 
the 2nd extraction [cm] 
Undissolved 
pellet  [%] 
Water 
2 1.9 0.0 25 
7 1.9 0.0 27 
30 % MeOH 
2 1.9 1.0 9 
7 1.8 1.0 18 
50 % MeOH 
2 1.9 0.8 45 
7 1.8 1.1 26 
80 % MeOH 
2 1.7 1.0 82 
7 1.9 1.0 73 
Therefore, another isolation step was necessary, aiming at the removal of highly hydrophilic 
sugars and salts. For this purpose, several mixtures of MeOH and water (0 %; 30 %; 50 %; 
80 % MeOH), each at pH of 2 and 7, have been analysed regarding their potential to dissolve 
the bioactive compound from the reverse extract (see 2.4.7). In short, 11 mg of the reverse ex-
tract have been dissolved in 1.0 ml of the respective mixture. After shaking for 30 min in the 
ultrasonic bath, the supernatants have been removed and subsequently analysed using 
E. coli K12 agar diffusion assays (see 2.3.1). The pellets were once more dissolved in 1 ml of 
the respective mixture and treated as described above. The resulting supernatants were also 
analysed using E. coli K12 agar diffusion assays (see 2.2.2). Meanwhile, the pellets were dried 
for 10 min at 60 °C and subsequently weighted (see Figure 23). As a result, already the first 
3.4 Streptomyces sp. Tü2401 93  
dissolution of the mixture of 80 % MeOH showed inhibition zones the same size as the water 
control samples, indicating that this mixture was sufficient to dissolve a considerable amount 
of the bioactive compounds. However, the supernatant of the second dissolution of the mix-
ture of 80 % MeOH was still bioactive even though the halo size was only half the size of the 
first dissolution. At the same time, the weight of the pellet after two extractions remained 
80 % of the initial weight, indicating that a substantial amount of the other hydrophilic com-
pounds remained in the pellet and were not soluble in 80 % MeOH (see Table 26). Hence, the 
whole reverse extract was extracted two times with 80 % MeOH and dried under reduced 
pressure, resulting in 18.2 g enriched reverse extract. Subsequently, this extract was analysed 
via HPLC-DAD, revealing a chromatogram that still contained several peaks. Therefore, addi-
tional purification steps were needed. 
 
Figure 23. Workflow for the extraction of the reverse extract of S. sp Tü2401.  
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3.4.5.1 Gel filtration chromatography  
The technique of SEC has already been introduced in chapter 3.3.4.1. However, there are ba-
sically two different types of SEC: One, gel permeation chromatography, being described 
ibidem. The other is gel filtration chromatography (GFC), here, a hydrophilic stationary phase 
and an aqueous mobile phase is used to separate water soluble molecules. The separation is 
in both cases based on the analytes size and affinity towards the stationary or mobile phase. 
GFC has at first been described in 1959 by Dr. Jerker Porath and Dr. Per Flodin as “A method 
for desalting and group separation”.281 Thus, this method seemed perfect for the final removal 
of salts and sugars from the purified reverse extract. Additionally, the retention time could give 
a first hint towards the size of the bioactive compound(s).282,283 
In order to identify the most suitable separation conditions, four different stationary phases, 
have been investigated (see Table 27) according to 2.6.2., Sephadex™ LH20; Sephadex™ G15, 
Bio-Gel® P2, and Toyopearl® HW40, each covering large exclusion limits starting from a few 
Dalton up to 5 kDa (Sephadex™ LH20) 
Table 27. Comparison of different stationary phases for GFC of the purified reverse extract. 
Material 
Exclusion 
Limits [Da] 
Column di-
mensions [cm] 
Flow rate 
[ml/h] 
Loading 
mass [mg] 
Fractionation 
interval [1/h] 
Kd* 
Sephadex™ LH20 ≤ 5000 2.5 x 90 34 104 3 0.60 
Sephadex™ G15 ≤ 1500 2.5 x 90 36 105 3 0.44 
Bio-Gel® P2 100 - 1800 2.5 x 90 45 103 3 0.46 
Toyopearl® HW40 100 - 10000 2.5 x 90 36 105 3 0.71 
  * Kd … distribution coefficient 
To compare the 4 stationary phases, the distribution coefficient Kd, a parameter, independent 
of column dimensions, has been determined (3).284 Kd values describe the extent to which a 
molecule diffuses into the pores of the stationary phase.281 Therefore, prior to the actual anal-
ysis, 1 ml of a 5mg/ml blue dextran solution has been subjected to each column. Blue dextran 
has an approximate molecular mass of 2000 kDa, therefore it is not able to penetrate into the 
pores of the stationary phase, thereby allowing the determination of each columns void vol-
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ume (V0). The total column volumes Vt has been estimated according to the column dimen-
sions. Finally, the purified reverse extract has been fractionated on each column. Each fraction 
has been analysed via E. coli K12 agar diffusion assays, giving the elution volumes Ve of the 
bioactive compound(s). A Kd of 0 represents high molecular weight compounds without any 
retention like blue dextran, whereas a low molecular weight compound, strongly interacting 
with the stationary phase will have a Kd ≥ 1. Accordingly, Kd values between 0 and 1 represent 
intermediate molecular weight compounds.284 
(3)  𝐾𝑑 =
𝑉𝑒− 𝑉0
𝑉𝑡− 𝑉0
 
In the case of the separation of known compounds, it would be beneficial to choose the sta-
tionary phase where Kd differs the most. However, for this separation, neither the bioactive 
compounds are known, nor the other matrix components from the purified reverse extract. 
Therefore, Toyopearl® HW40 has been chosen as stationary phase, since it exhibited the 
broadest exclusion limits on the one hand. And on the other hand, its Kd value of 0.71 points 
towards the biggest extend of diffusion of the bioactive compound(s) into the pores compared 
to all other stationary phases. Thus, Toyopearl® HW40 seemed to provide a sufficient separa-
tion of high molecular weight compounds and low molecular weight compounds simultane-
ously.
 
Figure 24. MS spectrum of the bioactive fraction at tR = 16 min. A cluster from m/z 458 to 
m/z 898 can be observed, with Δm/z of 44, indicating the presence of PEG in the sample.  
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Since this gravity flow chromatography was very time consuming, not the entire 18.2 g of the 
purified reverse extract have been separated, but rather 10.0 g. The active fractions have been 
combined and dried under reduced pressure, giving 1.1 g of bioactive fractions. However, the 
chromatograms of HPLC-DAD-ELSD analysis (see 2.6.4; Table 12) still exhibited a few peaks in 
the DAD (0 min ≤ tR ≤ 12 min), and also large peaks in the ELSD (12 min ≤ tR ≤ 18 min) (see 
Figure 26). Interestingly, microfractionation (see 2.6.4; Table 6) and subsequent E. coli K12 
agar diffusion bioassays (see 2.3.1) revealed a broad bioactive fraction ranging from 
tR = 16 min to tR = 18 min. In order to determine the respective masses, these fractions have 
been submitted to HPLC-MS analysis (see Table 8). As a result, the spectrum showed cluster 
with an m/z of 44, indicating the presence of PEG (see Figure 24 & Figure 25). These vast 
amounts of PEG might neither be a part of the media components, nor a metabolite from 
S. sp Tü2401. It might more likely originate from the antifoam agent Ucolub N115® 
(Fragol, Mülheim, Germany), consisting of Polypropylen- PEG, from which 2.0 ml had been 
added during large scale fermentation of S. sp. Tü2401 (see 2.2.4).285 Therefore, in order to 
identify the masses of the bioactive compounds, a method for the removal of the overlaying 
PEG needed to be developed. 
 
Figure 25. Structure of Polyethylene glycol (PEG), a polymere of ethylene oxide (C2H4O; 
M = 44.052 g/mol)  
A fast and efficient separation method is medium pressure liquid chromatography (MPLC).  
It allows the purification of large compound quantities and is therefore most suitable for the 
purification of crude extracts or preparative isolation of NP. In comparison to the widespread 
HPLC, where pressures of 400 - 500 bar are reached, MPLC is performed in general at pressures 
between 5 – 20 bar.286 Particle sizes of the stationary phases in MPLC columns range from 
25 µm – 40 µm, compared to 3 – 5 µm in HPLC columns. Therefore, in general MPLC can be 
operated at higher flow rates up to 100 ml/min.287 
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Figure 26. HPLC-DAD-ELSD chromatogram of the combined active fractions after GFC of the 
purifed reverse extract. The active fractions of the GFC have been combined and fractionated  
(see 2.6.4; Table 6). The fractions have been subsequently analysed in the E. coli K12 agar diffusion 
assays (see 2.3.1). Timeframe corresponding to fractions with antibiotic activity is highlighted with the 
green overlay. MPLC 
In order to determine the best separation conditions and the most suitable stationary phase 
material for MPLC purifications, it is most common to use thin-layer chromatography (TLC), 
since these results can be directly translated into MPLC.288 For this purpose two different, nor-
mal phase stationary phases (Silica gel 60 F254, Silica gel 60 Diol F254) and multiple mobile 
phases have been used to separate the bioactive fractions derived from GFC (see 2.6.2).  
Bioautography has been used to visualize the bioactive fractions on the TLC plate (see 2.3.4). 
It is a microbial screening method used to detect antimicrobial or antifungal activity in combi-
nation with TLC. 
(4)  𝑅𝑓 =
𝑚𝑖𝑔𝑟𝑎𝑡𝑖𝑜𝑛 𝑑𝑖𝑠𝑡𝑎𝑛𝑐𝑒 𝑖𝑛 𝑡ℎ𝑒 𝑚𝑜𝑏𝑖𝑙𝑒 𝑝ℎ𝑎𝑠𝑒
𝑚𝑖𝑔𝑟𝑎𝑡𝑖𝑜𝑛 𝑑𝑖𝑠𝑡𝑎𝑛𝑐𝑒 𝑜𝑓 𝑡ℎ𝑒 𝑠𝑜𝑙𝑣𝑒𝑛𝑡
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Table 28. Results of TLC experiments. Bioactive fractions from GFC have been separated on two 
different, normal phase stationary phases (Silica gel 60 F254, Silica gel 60 Diol F254), using various mobile 
phase compositions. The Rf values of the bioactive compound(s) have been determined via bioautog-
raphy. The shape of the corresponding halo is described in parenthesis. 
Stationary Phase Mobile Phase Bioactivity Rf 
Silica gel 60 F254  EA/MeOH/H20 (1:8:1; v/v/v) 0.2 (spot) 
Silica gel 60 F254  EA/MeOH/H20 [0.1 M citrate; pH 6] (1:8:1;v/ v/v) 0.25 (spot) 
Silica gel 60 F254  EA/MeOH/H20 [0.1 M citrate; pH 6] (1:7:2; v/v/v) 0.6 (spot) 
Silica gel 60 F254  EA/MeOH/H20 [HCl- KCl (0.1 M, pH 2] (1:8:1; v/v/v) 0.35 (spot) 
Silica gel 60 F254  EA/MeOH/H20 [HCl- KCl (0.1 M; pH 2] (1:7:2; v/v/v) 0.35 (spot) 
Silica gel 60 F254  MeOH/H20 (9:1; v/v) 0.15 (smear) 
Silica gel 60 F254  MeOH/H20 (9.5:0.5; v/v) 0.1 (smear) 
Silica gel 60 F254  MeOH/H20 (8:2; v/v) 0.6 (spot) 
Silica gel 60 F254  MeOH/H20 (7:3; v/v) 0.7 (spot) 
Silica gel 60 F254  DCM/MeOH/H20 (1:8:1; v/v/v) 0.2 (smear) 
Silica gel 60 F254  DCM/MeOH (2:8; v/v) 0.1 (smear) 
Silica gel 60 Diol F254  MeOH/H20 (2:8; v/v) no activity 
Silica gel 60 Diol F254  MeOH/H20 (2:8; v/v) + 1 % glacial acetic acid no activity 
In MPLC, column volumes (CV) (formula 5) instead of Rf values are used (formula 4).  
Literally, CV is the volume needed to elute the compound after injection.288  
(5) 𝐶𝑉 =  
1
𝑅𝑓
 
The TLC experiments have shown that Silica gel 60 Diol F254 stationary phases lead to a total 
loss of bioactivity. This is somehow surprising, since Diol phases are generally behaving as de-
activated silica gel with less polar activity.289 In contrast, normal phase Silica gel 60 F254 plates 
showed good separation capabilities, since variation of the media composition led to strong 
shifts of the Rf values. The two component mixture of MeOH and H2O, with no pH modification 
needed, had shown the greatest potential for the separation. An increase of the H2O ratio 
from 5 % to 30 %, lead to a drastic increase of Rf values from 0.1 to 0.7, corresponding to a 
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shift from 10 CV to 1.4 CV. Hence, a gradient MPLC using silica stationary phase and a 
MeOH/H2O gradient from 100 % MeOH to 70 % MeOH was assumedly most promising 
(see 2.6.1).  
In addition to the development of a suitable MPLC method, the TLC experiments were also 
used to get insights into the molecular structure of the bioactive compound(s). There are a 
number of staining methods to visualize the compounds on the TLC plate, which additionally 
allow the determination of functional groups that are contained within the molecule.290 
In this study, orcinol, as an agent typically used to detect sugars has been used (see 
2.6.1.1.1).291 This test is also called Bial’s test in honour of its inventor Manfred Bial.292 
Orcinol in combination with Fe3+ forms under acidic conditions a blue-green complex with 
pentose sugars, and a brown complex with hexose sugars.292 However, no sugars could be 
detected in the proximity of the bioactive spots. Additionally, also the presence of functional 
groups whose pKa is ≤ 5 has been tested using bromcresol green (see 2.6.1.1.2). At pH values 
below 5.4 this sulfonephthalein gets protonated, and thus turning from its dianionic form 
(blue) into the monoanionic form (yellow). However, no yellow spots could be detected in the 
proximity of the bioactive spots, indicating that the bioactive compound does not contain 
functional groups whose pKa is ≤ 5. Moreover, the presence of primary amines, e.g. amino 
acids and ammonia, has been analysed using ninhydrin (see 2.6.1.1.3). Ninhydrin condenses 
with a primary amine to form a Schiff base. After decarboxylation, amino-ninhydrin is formed, 
which subsequently condensates with another molecule of ninhydrin to form a purple prod-
uct, also called Ruhemann’s purple.293 But also this test was negative. 
After all, these staining tests did not give new insights into the structure of the bioactive com-
pound(s). But even though all tests were negative, it would be wrong to conclude that the 
bioactive compound(s) do not feature one or more of the tested functional groups. These 
staining assays always bear the risk that the compound(s) are bioactive in the bioautography 
tests, although their concentration is below the limit of detection in the staining assays. 
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Figure 27. HPLC-DAD-ELSD chromatogram of the combined bioactive fractions after MPLC. 
The bioactive fractions after MPLC have been analysed via HPLC using the Merck SeQuant® ZIC®-HILIC 
(see 2.6.4; Table 12) The chromatogram indicates the absence of PEG, since no signals occur 
in the ELSD. 
For the MPLC separation, 40 mg of the bioactive fractions from the GFC have been applied via 
dry loading (see 2.6.3) onto a 12 g Sepacore Silica HP column (Büchi Labortechnik AG, Flawil, 
Switzerland) and subsequently separated, using a gradient from 100 % MeOH to 50 % MeOH 
in 15 min at a flow rate of 18 ml/min. Samples were taken every minute and analysed using 
E. coli K12 agar diffusion assays (see 2.3.1). As a result, the bioactive fractions elute between 
10 and 19 CV with a maximum after of bioactivity after 16 CV. HPLC-DAD-ELSD analysis 
(see 2.6.4; Table 12) of the bioactive fractions revealed the absence of any signals in the ELSD. 
Thus, this method is suitable for the removal of PEG (see Figure 27). In total 200 mg of the 
bioactive fractions from the GFC have been separated using MPLC, resulting in 9 mg of PEG 
free bioactive fractions. 
Further analysis of the not bioactive fractions unveiled the elution of PEG very early during the 
separation, after 2 to 4 CV. 
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3.4.5.2 HPLC 
As mentioned above (see 3.4.5), already the first HPLC-DAD analysis of the CFS of S. sp. Tü2401 
submerse cultures have disclosed one major challenge for the identification of the bioactive 
compound(s). Since the normal ACN/H2O screening gradient, ranging from 5-100 % ACN on a 
Phenomenex Luna® C-18 column led to elution of the bioactive compound(s) contemporane-
ous with the injection peak (see Table 29) 
This indicates that the interactions between the bioactive compound(s) from S. sp. Tü2401 
submerse cultures and the mobile phase were much stronger, than the interactions with the 
stationary phase. Therefore, it was inevitable to develop an entire new method for these 
highly hydrophilic compound(s). For this purpose, different stationary phases have been ana-
lysed in order to increase retention. Therefore, an HPLC coupled to a fraction collector was 
used for the separations. The tR of the bioactive compound(s) was determined via E. coli K12 
agar diffusion assays (see 2.3.1). For the analysis, the freeze dried reverse extract (see 3.4.5) 
was dissolved in water and subsequently ACN was added until the solution finally consisted of 
80 % ACN. After centrifugation, the supernatant was used for the separation. 
It is well known that reversed phase columns differ in their separation behaviour depending 
on the aliphatic chain length and the degree of endcapping. The longer the carbon chain and 
the more thoroughly endcapped, the less polar interactions between the solute and the sta-
tionary phase can be observed.294,295 But not only these obvious differences lead to altered 
retention times, also endcapped C-18 columns from different vendors can have different sep-
aration characteristics.295  
Therefore, the Nucleosil 100 C-18 column has been tested as an alternative reversed phase to 
the Phenomenex Luna® C-18 column. However, using the same separation conditions did not 
improve the separation of the bioactive compound(s), as they still eluted at the same time as 
the injection peak (see Table 29) 
Furthermore, the Nucleosil 100 C-8 column has also been tested as a less unpolar reversed 
phase column. Referring to the producer, its separation is still based on hydrophobic (van der 
Waals) interactions but offers column additional slight residual silanol interactions compared 
to the Nucleosil C-18, since they are not endcapped.296 These hydroxyl groups are now able to 
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have dipole-dipole interactions or to form hydrogen bonds with the analyte(s). For the sepa-
ration, the same method as for the Phenomenex Luna® C-18 column has been applied.  
However, the bioactive compound(s) were not retained (see Table 29). 
Table 29. Columns & conditions for the separation for albomycin δ1 & δ2 
 
The Kinetex® Polar C-18 column from Phenomenex is a silica based stationary phase, modified 
with C-18 chains, TMS endcaps and small polar groups.297 It provides therefore as well polar 
and non-polar retention. Due to the reduced particle size the column was operated at a flow 
rate of 1.2 ml/min instead of 2.0 ml/min. Hence, to maintain comparable separation conditions 
to the other reversed phases, it was necessary to prolong the run by 25 % to 20 min, while the 
gradient from 5 % to 100 % ACN remained unchanged. The agar diffusion assay revealed an 
increase in retention since the bioactive compound(s) eluted between 0 and 2 min (see Table 
Column 
Separation conditions tR of the bio-
active com-
pound(s)[min] 
mobile Phase Gradient [%] 
Flow 
[ml/min] 
Time 
[min] 
Nucleosil 100 C-8; 5 µm; 100  Å; 
4.6 mm x 125 mm 
A: H2O;B: ACN + 
0.1 % FA 
B: 0 - 100 2.0 15 0 
Nucleosil 100 C-18; 5 µm; 100  Å; 
4.6 mm x 125 mm 
A: H2O;B: ACN + 
0.1 % FA 
B: 0 - 100 2.0 15 0 
Luna® C-18; 5 µm; 100  Å; 4.6 mm 
x 250 mm 
A: H2O;B: ACN + 
0.1 % FA 
B: 5 - 100 2.5 20 0 
Kinetex® Polar C-18; 2.6 µm; 
100  Å; 4.6 mm x 150 mm 
A: H2O;B: ACN + 
0.1 % FA 
B: 5 - 100 1.2 20 0 - 2 
Luna® NH2; 5 µm; 100  Å; 4.6 mm 
x 250 mm 
A: H2O;B: ACN + 
0.1 % FA 
B: 80 (iso-
cratic) 
2.0 20 2.5 - 5.5  
SeQuant® ZIC®-HILIC; 3.5 µm; 
100  Å; 4.6 mm x 150 mm 
A: 10 mM 
NH4CH3COO;             
B: ACN + 0.1 % FA 
B: 80 (iso-
cratic) 
0.8 45 12.5 - 22.5  
XBridge BEH Amide; 5 µm; 130  Å; 
4.6 mm x 250 mm  
A: ACN/H2O/100mM 
NH4COO pH3 (5:4:1; 
v/v/v)         B: 
ACN/100mM 
NH4COO pH3 (9:1)   
B: 80 - 60 1.0 35 21.0 - 23.0; 
27.0 - 29.0 
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29). Even though the Kinetex® Polar C-18 column slightly improved the retention of the bioac-
tive compound(s), the spread of the bioactivity over 2 min indicate a very broad peak and thus 
poor selectivity.  
Hydrophilic Interaction Liquid Chromatography (HILIC), using either the Luna® NH2 column, the 
SeQuant® ZIC®-HILIC column, or the XBridge BEH Amide column substantially improved the 
separation in terms of retention time and selectivity. HILIC is an alternative normal phase liquid 
chromatography approach, designed for the separation of small polar compounds on polar 
stationary phases.298 Nevertheless, it also has intersections with other chromatographic appli-
cation, since it combines normal phase chromatography with ion chromatography and even 
with reversed phase chromatography.298 The stationary phases are in general traditional polar 
stationary phases, as used in normal phase LC, like silica, amino or cyano.298–303 However, the 
mobile phases are more similar to those used in classical reversed phase LC.298,302–304 
Furthermore, like in ion chromatography, even charged compounds can be analysed using 
HILIC. These characteristics makes HILIC a perfect method for the analysis of compounds that 
elute near the void in reserved-phase chromatography.298 Additionally, it has also been suc-
cessfully combined with MS analysis.298 HILIC has been used to analyse a broad variety of hy-
drophilic compounds like carbohydrates and peptides, and is becoming more popular also in 
terms of pharmaceutical analysis.305–307 Even though the separation of polar compounds on 
polar stationary phases with unpolar/aqueous mobile phases has been used for 30 years, 
mostly in carbohydrate analysis, it was Dr. Andrew Alpert who introduced the acronym HILIC 
in 1990.304,308 Ever since, the interest in the method is rising, evident in the number of scientific 
HILIC papers since 2003, reaching 500 new publications in 2012.298,303,309 Even though signifi-
cant progress has been made in elucidating the retention mechanism of HILIC, there are still 
questions to be answered.303 Various techniques (e.g. frontal analysis, titration, etc.) have con-
firmed the presence of a water-rich layer on the surface of the stationary phase.303 This indi-
cates that partition of the analyte between this layer and the mobile phase is the predominant 
factor for retention.308 However, the actual retention mechanism of HILIC is much more com-
plex, since also adsorption and electrostatic interactions might be involved in the separa-
tion.303,309,310 It is assumed that the individual separation mechanism depends on the analyte, 
the mobile phase composition, and also the functionalities of the stationary phase, also 
termed “LC Retention Troika”.303,311 Hence, also mobile phase pH, its ionic strength, and the 
organic phase itself have an effect on the separation.161,303,312  
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Three different polar stationary phases, Phenomenex Luna® NH2, SeQuant® ZIC®-HILIC, and 
XBridge BEH Amide, have been analysed for their potential to separate the bioactive com-
pound(s) from reverse extract of S. sp. Tü2401 (see Table 29). 
The Phenomenex Luna® NH2 column consists of a silica base modified with aminopropyl 
groups. In combination with acidic pH values, the positively charged amino functions facilitate 
great selectivity for acidic compounds due to coulomb interactions.161 In order to separate the 
bioactive compound(s), an isocratic method was used, where the mobile phase consists of 
80 % ACN, 20 % H20 and 0.1 % FA (see Table 29). As a result, the tR of the bioactive compounds 
was between 2.5 - 5.5 min, thus enabling a better retention than on all the reversed phases. 
However, the signal was still very broad, indicating once more poor selectivity. Moreover, in 
contrast to the vendor’s description, the application of this method to HPLC-MS analysis re-
vealed insufficient stability of the stationary phase, leading to a high signal-to-noise ratio. 
Therefore, the Phenomenex Luna® NH2 column was unsuitable for the isolation and dereplica-
tion of the bioactive compound(s). 
The Merck SeQuant® ZIC®-HILIC column is composed of a zwitterionic sulfobetaine silica base. 
These zwitterionic phases are known to form a firm water layer on the surface and provide 
additional coulomb interactions to ionic analytes.310 As recommended by Merck, the column 
was operated at a flow rate of 0.8 ml/min. Accordingly, the analysis time was increased to 
45 min. Also with this column, an isocratic separation method was used, with a mobile phase 
consisting of 20 % of a 10 mM solution of NH4CH3COO and 80 % ACN (see Table 29). The tR of 
the bioactive compound(s) ranged during the first analysis from 14 to 17 min. However, rep-
etition of this separation resulted in considerable fluctuations of the tR over a range from 
12.5 min to 22.5 min. Since the equipment as well as all the solvents and even the sample 
were the same, this is an indication for insufficient column equilibration or the sensitivity of 
the bioactive compound(s) towards a yet unknown and uncontrolled factor. MS analysis of the 
bioactive fractions compared to non-bioactive fractions did not reveal any masses unique to 
the bioactive fractions. Interestingly, there are no signals detectable in the chromatogram 
during the time the bioactive fractions elute - neither UV-signals nor ELSD-signals. The light 
scattering detector is used to detect and even quantify compounds that do not feature a chro-
mophore and are less volatile than the mobile phase.313,314 Mobile phase composition, gas 
flow as well as nebulizer and vaporizer temperature are parameters that can influence the 
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sensitivity of the ELSD.161,315 An increase in sensitivity for carbohydrates has been reported to 
result from an increase in vaporizer temperature.161,315–317 Accordingly, vaporizer tempera-
tures ranging from the standard 40 °C to 60 °C (5 °C steps) have been tested. An increase in 
sensitivity especially for compounds eluting between 8 and 12 min was observable.161  
However, still no signals were detectable in the timeframe where the bioactive compound(s) 
elute.161 Hence, either the compound(s) are more volatile than the mobile phase, or their con-
centration is below the detection limit of the ELSD. Even though analysis using the  
Merck SeQuant® ZIC®-HILIC column resulted in good retention times, the inconsistency of the 
tR of different runs as well as the broad range of elution still indicate no good selectivity for 
the bioactive compound(s) at the conditions chosen. 
The last column that has been tested was the Waters XBridge BEH Amide. This column has 
been chosen, since it is stable over a broad range of mobile phase pH [2 – 11]. It is composed 
of a silica base that is trifunctionally-bonded via an ethylene bridged hybrid linker unit to an 
amide function. According to the manufacturer, this column has been especially designed to 
separate extremely polar compounds. This column has been operated at a flow rate of 
1 ml/min. As mentioned above, the pH of the mobile phase is a crucial parameter in HILIC 
separations. Therefore, 3 different pH values have been compared, pH 3, 6, and 8.5. A 
10mM NH4CHOO solution at the respective pH was chosen as solvent A, whereas ACN served 
as solvent B. In contrast to the other columns, this time a gradient method was developed, 
starting with isocratic conditions (95 % B for 5 min), followed by a gradient over 20 min to 
60 % B, which was finally kept for 5 min. In order to produce robust results, the equilibration 
time between injections is crucial for HILIC. Therefore, 10 CV have been used to equilibrate 
the column.318 The tR of the bioactive compound(s) varied just slightly, while at pH 8.5 the 
bioactive fractions eluted in the range between 21 and 26 min, it shifted to 23 to 26 min at 
pH 3 and 6. Even though the tR are almost the same, the peaks shape became more narrow at 
lower pH values. Therefore, in all following experiments the pH was adjusted to 3. 
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Figure 28. HPLC-DAD-ELSD chromatogram of the PEG free bioactive fractions after MPLC, 
using the Waters XBridge BEH Amide column 
In addition to the pH, also the buffer concentration is crucial for HILIC separation.303 Accord-
ingly, its influence on the separation was analysed. Thus, the mobile phase composition was 
changed, so that solvent A was composed of ACN/H2O [pH3]/100mM NH4CHOO (5:4:1 (v/v/v)) 
and solvent B of ACN/100mM NH4CHOO [pH3] (9:1 (v/v)). The other separation parameters 
remained unchanged. The constant buffer concentration of 100mM NH4CHOO indeed had an 
effect on the separation in this regard that the bioactive fractions elute in the narrow time 
frame between 27 and 29 min. Hence, in following analyses, the solvent composition was re-
mained as described in order to maintain a constant buffer concentration. Moreover, in order 
to get a faster elution of the bioactive compound(s), the slope of the gradient has been re-
duced. Hence, the initial isocratic conditions were set to 80 %, respectively 70 % B. All other 
parameters remained unchanged. The separation, using initial isocratic conditions of 70 % B, 
decreased the tR drastically, so that the bioactive compounds eluted between 6 and 9 min. 
However, during the same time many other uncharacterized peaks occurred. Therefore, this 
method seemed insufficient for separation of the bioactive compound(s). Meanwhile, the sep-
aration with the initial isocratic conditions of 80 % B did not decrease the tR, since the bioactive 
fractions eluted between 21 and 29 min (see Figure 28). However, the bioassays revealed two 
separate bioactive fractions, one ranging from 21 to 23 min and the other ranging from 27 to 
29 min. Subsequent analysis of the bioactive fraction tR= 27 min revealed a single peak 
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(see Figure 29). Therefore, the Waters XBridge BEH Amide column in combination with this 
method has been used for all further isolation experiments (see Table 29). 
 
Figure 29. HPLC-DAD-ELSD chromatogram of the bioactive fraction tR = 27 min using the Wa-
ters XBridge BEH Amide column 
3.4.5.3 Dereplication of the hydrophilic metabolites from S. sp. Tü2401 liquid 
cultures 
HPLC coupled with tandem mass spectrometry is a technique, where downstream to an HPLC 
multiple steps of mass spectrometry selection are performed. Leading to selection of defined 
masses during the first stage of mass spectrometry and subsequently to the fragmentation of 
these ions in between the first and the second mass spectrometry.319 The second mass spec-
trometry step is needed to detect the fragment ions. The fragmentation pattern is compound 
specific and thus can be used to identify or dereplicate compounds.196,320–322 Several web tools 
use fragmentation patterns for dereplication, e.g. MetFrag, CFM-ID.323–327 These tools have in 
common that they need an accurate mass as well as the fragment pattern of the compound 
that needs to be dereplicated for precise predictions. In the next step, this pattern is compared 
to a database of fragmentation patterns. However, every tool has its own approach for the 
generation of the underlying database. 
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MetFrag creates in-silico fragmentation patterns, by simply breaking every bonds of candidate 
molecules from different databases e.g. ChemSpider.com, and subsequently scoring the likeli-
hood for each break. Finally, these in-silico fragmentation patterns are matched against the 
mass list of the compound that needs to be dereplicated, resulting in a score, indicating the 
quality of the candidate spectrum assignment.323 
CFM-ID is based on Competitive Fragmentation Modelling (CFM), a probabilistic generative 
model especially for ESI-MS2 data that uses machine learning technique, able to learn from the 
data. Like MetFrag it finally ranks a list of candidate structures according to their matching 
scorre.325  
 
Figure 30. Isolation scheme for albomycin δ1 and δ2. 
In order to isolate the bioactive compounds produced by S. sp. Tü2401 in submerse culture, 
many purification steps have been necessary to end up with bioactive single compound iso-
lates (see Figure 30). The bioactive fractions tR= 21 min and tR= 27 min were finally analysed 
using HPLC-MS2 (2.6.5), resulting in m/z [M+H]+: 1004.2849 (tR= 21 min) and 1046.3049  
(27 min). The respective fragmentation pattern has been subsequently submitted to MetFrag. 
With the help of this tool, it was possible to identify the compounds albomycin δ1 and δ2 as 
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possible structures for the bioactive compounds. In order to confirm these findings, the HPLC-
MS data were compared to those of albomycin δ1 and δ2. After obtaining, these two com-
pounds from an in-house compound library, they have been separately dissolved in 80 % ACN 
and submitted to the same analysis as the single compound isolates from S. sp. Tü2401.  
The data revealed equivalence in terms of retention times as well as of isotope patterns and 
masses (see Figure 31). Thus, it is legitimate to assign the bioactivity of Streptomy-
ces sp. Tü2401 to albomycin δ1 and δ2. 
 
Figure 31. HPLC chromatograms and mass spectra of bioactive single compound isolates of 
S. sp. Tü2401 and albomycin δ1 and δ2 control samples. A – D show the extracted ion chromato-
grams (EIC) of albomycin δ1 (A), albomycin δ2 (C), bioactive fraction tR = 21 min from S. sp. Tü2401 (B), 
and bioactive fraction tR = 27 min from S. sp.  Tü2401. The first peaks in A and C are due to control 
samples that were highly concentrated, leading to an additional peak contemporaneous with the in-
jection peak. E & F depict the mass spectra of albomycin δ1 (E) and δ2 (F) that could be found in the 
control samples as well as the bioactive isolates of S. sp. Tü2401 
Albomycins, originally called griseins, have been isolated from a Streptomyces griseus strain in 
1947 in the Waksman Lab (see 1.3).328–330 The structure of the albomycins were finally eluci-
dated 35 years after the first reports in 1982 by Benz et al..331,332 Until now, three different 
albomycins are known: δ1, δ2, and ε (see Figure 32). They are composed of a  
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tri-δ-N-hydroxy-L-ornithine peptide siderophore and thioribosyl nucleoside moiety within 
six consecutive chiral centres.331 This thionucleoside is considered to be the warhead of the 
albomycins, since it differs only in the C-4 substituent of the pyrimidine nucleobase.331 
The single thioribosyl nucleoside moiety of albomycin δ2, designated as SB-217452, has been 
isolated from a Streptomyces sp. ATCC 700974 strain.333 It had shown moderate inhibitory ac-
tivity against bacterial seryl tRNA synthetases (SerRS) with IC50 values of 8 mM.333,334  
Besides this, SB-217452 exhibits weak antibacterial activity.333 Various studies have confirmed 
the importance of the siderophore moiety for the bioactivity of the albomycins.335,336  
Gram-negative bacteria like Escherichia coli and Salmonella facilitate secrete the siderophore 
ferrichrome under iron limitation, which can subsequently be taken up again via a siderophore 
receptor.335,336 In fact, the siderophore moiety of albomycins mimics ferrichrome. Thus, they 
are taken up via the same route, hence this strategy is referred to as “Trojan Horse” strat-
egy.335,336 Once internalised, the peptide is hydrolysed, releasing the active thioribosyl nucleo-
side moiety, and thus exerting the antibacterial activity.335 Accordingly, resistance mechanisms 
involve either a loss of peptidase activity or reduced uptake, and have been reported to de-
velop rapidly.336 This phenomenon was confirmed in the E. coli K12 bioactivity tests using 
S. sp. Tü2401 (see Figure 22). 
 
Figure 32. Structure of different albomycins contain a thioribosyl nucleoside moiety (red) linked 
to an iron- chelating hydroxamate siderophore (blue) through a serine residue  
(Adapted from Zeng et al. 2009)337 
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Due to their structures, the albomycins are assigned to the family of sideromycins that also 
comprises the naturally occurring compounds ferrimycin A1 from Streptomyces griseoflavus 
and the salmycins A – D from Streptomyces violaceus.335,338,339 They are all composed of  
hydroxamate-type siderophores and suffer all from the same resistance mechanism develop-
ment that affects the siderophore uptake.340  
Albomycins exhibit antibacterial activities against Gram-positive, including multi-drug resistant 
strains, but also against Gram-negative bacteria.331,341–343 Even though albomycin δ2 was found 
to be more potent against most of the tested organisms, albomycin δ1 turned out to be very 
active against Neisseria gonorrhoeae ATCC 49226 with a MIC of 3.9 ng/ml, while albomycin δ2 
was inactive.331 This underlines the significance of the C-4 substituent for the biological activity 
towards different organisms. Particularly remarkable activities are the MIC values of 10 ng/ml 
against Streptococcus pneumoniae respectively 5 ng/ml against Escherichia coli, illustrating 
that albomycins are almost tenfold more potent than penicillin.331,344 This has also been con-
firmed in screening against 27 clinical isolates of S. pneumoniae and S. aureus, where albomy-
cin δ2 has been compared with ciprofloxacin, vancomycin, and penicillin G.331 Albomycin δ2 
was mostly even more potent than all these antibiotics, showing in some case more 1000 times 
lower MIC values.331 The presence of iron has a substantial influence on the biological activity 
of albomycin δ2 against S. pneumoniae, since its antibiotic activity was not only increased dur-
ing iron limitation, but also clinical isolates that were resistant under normal conditions be-
came susceptible under iron-depleted conditions.331 Activity against S. aureus and E. coli was 
not influenced by iron concentration.331 
In addition to these promising antibacterial activity data, albomycins did not exhibit toxicity 
during in-vivo studies in mice and have also been well tolerated.331,343 Thus it is no surprise 
that albomycins have already been successfully used in clinics in the Soviet Union.343  
In recent years not only a total synthesis for albomycins δ1, δ2 and ε has been developed, but 
also the BGC has been identified, making albomycin a valuable target for synthetic biol-
ogy.331,334 
BLAST analysis of the genome of S. sp. Tü2401 confirmed the presence of the albomycin BGC. 
However, since this genome cluster has not been identified by antiSMASH, the albomycins 
could not be identified earlier during the dereplication process.   
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3.5 Streptomyces sp. AcE210 
In previous works, Streptomyces sp. AcE210 has been isolated from the root nodules of an 
alder tree. The ethyl acetate extract showed antibacterial activity against a co-isolated Bacil-
lus sp. Subsequent HPLC analysis of this EA extract revealed 6 compounds that could not been 
dereplicated, using an in-house database (see 2.6.4; Table 8). Within the course of this thesis, 
these compounds as well as another, co-eluting derivative could be identified as xanthocidin 
and congeners. Even though xanthocidin has first been described in 1966, the other 6 com-
pounds have never been isolated from a Streptomyces sp. before.345 Xanthocidin belongs to 
the small group of cyclopentanone antibiotics, that in addition comprises of pentenomycins, 
vertimycin, sarkomycin and methylenomycins.346–349 
Moreover, the structural similarities of xanthocidin and some of its congeners to the methyle-
nomycins A, B, and C, led to a biosynthesis hypothesis. Feeding studies with isotopically la-
belled [13C5]-L-valine confirmed, that Streptomyces sp. AcE210 employs an isobutyryl-CoA 
starter unit, resulting in a branched side chain in xanthocidin. Moreover, analysis of the ge-
nome sequence of Streptomyces sp. AcE210 revealed a cluster of homologues to the 
mmy genes involved in methylenomycin biosynthesis. 
The results have been summarized in the publications A and B.  
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A. Xanthocidin Derivatives from the Endophytic Streptomyces sp. AcE210 Provide In 
     sight into Xanthocidin Biosynthesis 
Ortlieb, Nico; Bretzel, Karin; Kulik, Andreas; Haas, Julian; Lüdeke, Steffen; Keilhofer, 
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B. Draft Genome Sequence of the Xanthocidin-Producing Strain Streptomyces sp.  
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4. Conclusion  
The present work aimed at the identification of biologically active natural products from Ac-
tinobacteria. In order to facilitate a time and space efficient cultivation of the Tübingen strain 
collection of Actinobacteria, a suitable tool was developed, combinable with multiple agar dif-
fusion assays, utilizing various monitor strains. As a proof of concept, the Tübingen strain col-
lection was initially screened against one monitor strain, developed to identify compounds 
that interfere with a key player of QS signal transduction. 
Furthermore, the aim of the theses was also the identification and characterisation of new 
natural products with rare structural features, independent from their bioactivity. Within this 
scope, Streptomyces sp AcE210 was analysed due to its potential to synthesise a rare cyclo-
pentanone antibiotic – xanthocidin as well as several yet uncharacterized derivatives. 
This chapter will summarize the key findings of the thesis and present resulting deductions. 
4.1 Development of a screening system 
In the present work a cultivation system for Actinobacteria was developed, allowing the culti-
vation of 96 different strains on agar in stainless steel MTP. All cultivation and screening sys-
tems reported to date are based on submerse cultivation systems. Even though Actinobacteria 
are able to grow and produce secondary metabolites in submerse cultures, their lifecycle indi-
cates that they are naturally growing attached to any kind of surface. Keeping in mind the 
tremendous influence of the cultivation conditions on the production of secondary metabo-
lites, the herein described combined cultivation and screening platform for Actinobacteria 
could be a promising tool for the fast and efficient identification of new bioactive NP.  
To the best of my knowledge, it is the first tool that allows simultaneous cultivation of multiple 
Actinobacteria strains on agar and subsequent analysis of these strains in agar diffusion assays. 
4.2 Exploitation of the developed system to search for bioactive compounds 
In order to proof the benefit of the developed cultivation and screening system, the Tübingen 
strain collection has been cultivated using ISP2 and ISP3 medium and subsequently screened 
against the S. aureus PC322 assay that has been developed by Nielsen et al..147 
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82 strains showed quorum sensing inhibition activity, while 284 strains exhibited antibacterial 
activity, and 866 strains did not reveal any activity. These results indicate the great potential 
of this tool since it allows the identification of bioactive strains in a fast and comprehensive 
way. Moreover, the bioactivity assay that is coupled to the cultivation system is interchangea-
ble. Hence, different bioactivities could be analysed using this tool. The only limit so far is that 
the bioactivity assay needs to be an agar diffusion assay. Hence, the scope of the screening 
has been extended and, in cooperation with other scientists, more monitor strains have al-
ready been used successfully. 
Two of the most promising strains from the screening have been analysed in regard to their 
bioactive compounds, S. sp. Tü2700 exhibiting QS inhibition activity, and S. sp. Tü2401 showing 
antibacterial activity. Phylogeny analysis of these two strains using the bioinformatics tool au-
toMLST revealed their affiliation to the genus Streptomyces. 
A sufficient purification protocol for the isolation of the bioactive compound of S. sp. Tü2700 
was developed and led to the dereplication of oxazolomycin A. This oxazole polyene γ-lac-
tam/β-lactone antibiotic compound has been first isolated in 1985 by Uemura et al.210 S. au-
reus PC322 bioactivity assays with and without staining agent revealed that oxazolomycin A 
doesn’t inhibit QS, but instead exhibits partially antibacterial activity, resulting in misleading 
hazy halos. Even though it is known for its antiviral, cytotoxic and antibacterial behaviour as 
well as its potential to inhibit plant transformation, antibacterial activity against S. aureus has 
only been described for its methylated derivative KSM-2690 B so far. Moreover, except for glu-
cose, no compounds have been reported yet that create hazy halos in the S. aureus PC322 
assay, without interfering with its agr system yet. Therefore, oxazolomycin A and possibly 
KSM-2690 B could be considered as compounds leading to false positive outcomes. Hence, in 
order to eliminate those compounds early in the screening process, it would be advisable to 
analyse, in the future, every positive hit in a second assay. This second assay should be per-
formed without supplementing X-Gal in the agar.  
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Characterisation of S. sp. Tü2401 revealed that this strain was able to produce two different 
compounds, depending on the cultivation conditions. On agar the highly cytotoxic compound  
C-1027 was produced. This compound was originally isolated in 1988 from Streptomyces glo-
bisporus.It belongs to the small family of enediyne compounds that comprises to 
date 11 members. Three of these, namely neocarcinostatin, calicheamicin and C-1027 are cur-
rently in clinical trials, or are already used in the clinic.250 The success rate for these compounds 
reaching the clinic of ca. 30 %, makes these compounds a very promising target for antitumor 
drug development. Since bioinformatic analysis of bacterial genomes have revealed that ene-
diyne BGC are highly abundant among Actinobacteria (6.3 %), it is astonishing that the number 
of compounds belonging to this group is still small. On the other hand, this ratio indicates that, 
within the Tübingen strain collection, statistically 75 enediyne producing strains are yet to be 
identified. Since C-1027 was exclusively produced on agar, this compound serves as a prove of 
concept for the cultivation/screening tool and underlines the huge potential of the Tübingen 
strain collection for the identification of potential drug candidates. Moreover, many bioactive 
strains that have been identified during the screening are not characterized yet.  
Therefore, a profound dereplication process for those compounds is recommended in order 
to save time and resources. 
The other antibacterial compounds produced by S. sp. Tü2401 could not been isolated, due to 
their hydrophilicity using classical isolation approaches. The development of a specific purifi-
cation procedure led to the identification of albomycin δ1 and δ2. Even though these sidero-
mycins are known since 1947, their activity against Gram-negative bacteria like E. coli has put 
them back into the spotlight of researchers in recent years. Detailed bioactivity studies against 
a panel of clinical isolates as well as against multi resistant strains have shown their great po-
tential, since albomycin δ2 exhibited in some case more 1000 times lower MIC values against 
S. pneumoniae and S. aureus compared to ciprofloxacin, vancomycin, and penicillin G.331 
MIC values of 5 ng/ml against Escherichia coli illustrate that albomycins are almost tenfold 
more potent than penicillin.331,344 Besides, albomycins did not exhibit toxicity during in-vivo 
studies in mice and have also been well tolerated.331,343 In times where multi resistant strains 
are on the rise, and antibiotics active against Gram–negative bacteria are scarce, albomycins 
are promising drug candidates.  
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4.3 Investigations of the xanthocidin biosynthesis 
The isolation and structural characterization of xanthocidin and six new derivatives from the 
endophytic Streptomyces sp. AcE210 led to the elucidation of the biosynthesis for this  
cyclopentanone antibiotic as well as to the identification of its putative BGC. The family of 
cyclopentanone antibiotics comprises 5 major compounds. However, the biosynthesis has pre-
viously only been studied for methylenomycin. Even though xanthocidin has already been iso-
lated already in 1966, the biosynthesis has not been described yet. Since the original producer 
strain had lost its ability to produce xanthocidin, total synthesis has been the only way to ob-
tain this compound.193 Therefore, only few studies on the biological activity of xanthocidin 
have been performed.193 The potential of the cyclopentanone antibiotics to serve as potential 
new drug candidates is exemplified by sarkomycin, another member of this family that has 
been used in antitumor therapy in Japan.193 Hence, the identification of a new xanthocidin 
producer and the xanthocidin biosynthesis, as well as a putative BGC could enable a sustaina-
ble biotechnological production of xanthocidin. Additionally, feeding of unusual starter 
units/amino acids could result in the production of new derivatives with alternated bioactivity.  
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aa Amino acid 
ACN Acetonitrile 
AIP Autoinducing peptides 
antiSMASH Antibiotics and secondary metabolite analysis shell 
BGC Biosynthetic gene cluster 
BLAST Basic Local Alignment Search Tool 
CFS Cell free supernatant 
CFU Colony-forming units 
CV Column volumes  
DAD Diode array detector 
DCM Dichlormethane 
DNA Deoxyribonucleic acid 
EA Ethyl acetate 
eDNA Environmental DNA 
ELSD Evaporative light scattering detector 
FA Formic acid 
FDA U. S. Food and Drug Administration 
GFC Gel filtration chromatography  
HCl Hydrochloric acid 
HPLC High performance liquid cromatography coupled to a mass spectrometer 
HPLC-MS High performance liquid cromatography cou 
HR-MS High resultion mass spectrometry 
HSAF Heat-stable antifungal factor 
HTP High-throughput 
ISP International Streptomyces Project 
LC Liquid chromatography 
MeOH Methanol 
MIC Minimal inhibitory concentration 
MoA Mode of action 
MPLC Medium pressure liquid chromatography 
MS2 Tandem mass spectrometry 
MTP Microtiter plate 
NaOH Sodium hydroxide 
NMR Nuclear magnetic resonance spectroscopy 
NP Natural product 
PEG Polyethylene glycol  
pHPLC Preparative HPLC 
PTM Polycyclic tetramate macrolactams  
QS Quorum sensing 
QSI Quorum sensing inhibition 
rpm Revelations per minute 
rRNA Ribosomal RNA 
SEC Size-exclusion chromatography 
SMA Styrene-co-maleic acid 
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TLC Thin-layer chromatography 
tR Relative retention time 
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Figure 20; S. 87 
 
